<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Immunol</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Immunology</journal-title>
</journal-title-group>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29942301</article-id>
<article-id pub-id-type="pmc">6004768</article-id>
<article-id pub-id-type="doi">10.3389/fimmu.2018.01103</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Inherited Immunodeficiencies With High Predisposition to Epstein–Barr Virus-Driven Lymphoproliferative Diseases</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Latour</surname>
<given-names>Sylvain</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="corresp" rid="fn001">*</xref>
<uri xlink:href="https://frontiersin.org/people/u/30559" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Winter</surname>
<given-names>Sarah</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://frontiersin.org/people/u/540004" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Laboratory of Lymphocyte Activation and Susceptibility to EBV infection, INSERM UMR 1163</institution>, <addr-line>Paris</addr-line>, <country>France</country></aff>
<aff id="aff2"><sup>2</sup><institution>Imagine Institute, Paris Descartes University, Sorbonne Paris Cité</institution>, <addr-line>Paris</addr-line>, <country>France</country></aff>
<aff id="aff3"><sup>3</sup><institution>Equipe de Recherche Labéllisée, Ligue National contre le Cancer</institution>, <addr-line>Paris</addr-line>, <country>France</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Isabelle Meyts, KU Leuven, Belgium</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Jeffrey I. Cohen, National Institutes of Health (NIH), United States; Arndt Borkhardt, Heinrich Heine Universität Düsseldorf, Germany; Stuart G. Tangye, Garvan Institute of Medical Research, Australia</p>
</fn>
<corresp id="fn001">*Correspondence: Sylvain Latour, <email>sylvain.latour@inserm.fr</email></corresp>
<fn fn-type="other" id="fn002">
<p>Specialty section: This article was submitted to Primary Immunodeficiencies, a section of the journal Frontiers in Immunology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>04</day>
<month>6</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<year>2018</year>
</pub-date>
<volume>9</volume>
<elocation-id>1103</elocation-id>
<history>
<date date-type="received">
<day>15</day>
<month>2</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>02</day>
<month>5</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2018 Latour and Winter.</copyright-statement>
<copyright-year>2018</copyright-year>
<copyright-holder>Latour and Winter</copyright-holder>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Epstein–Barr Virus (EBV) is a gamma-herpes virus that infects 90% of humans without any symptoms in most cases, but has an oncogenic potential, especially in immunocompromised individuals. In the past 30 years, several primary immunodeficiencies (PIDs) associated with a high risk to develop EBV-associated lymphoproliferative disorders (LPDs), essentially consisting of virus-associated hemophagocytic syndrome, non-malignant and malignant B-cell LPDs including non-Hodgkin and Hodgkin’s types of B lymphomas have been characterized. Among them are <italic>SH2D1A</italic> (<italic>SAP</italic>), <italic>XIAP, ITK, MAGT1, CD27, CD70, CTPS1, RASGRP1</italic>, and <italic>CORO1A</italic> deficiencies. Penetrance of EBV infection ranges from 50 to 100% in those PIDs. Description of large cohorts and case reports has refined the specific phenotypes associated with these PIDs helping to the diagnosis. Specific pathways required for protective immunity to EBV have emerged from studies of these PIDs. SLAM-associated protein-dependent SLAM receptors and MAGT1-dependent NKG2D pathways are important for T and NK-cell cytotoxicity toward EBV-infected B-cells, while CD27–CD70 interactions are critical to drive the expansion of EBV-specific T-cells. CTPS1 and RASGRP1 deficiencies further strengthen that T-lymphocyte expansion is a key step in the immune response to EBV. These pathways appear to be also important for the anti-tumoral immune surveillance of abnormal B cells. Monogenic PIDs should be thus considered in case of any EBV-associated LPDs.</p>
</abstract>
<kwd-group>
<kwd>immunodeficiencies</kwd>
<kwd>Epstein–Barr virus</kwd>
<kwd>lymphoproliferative disorders</kwd>
<kwd>genetic predisposition to disease</kwd>
<kwd>T lymphocytes</kwd>
<kwd>T lymphocyte activation</kwd>
</kwd-group>
<counts>
<fig-count count="1"></fig-count>
<table-count count="2"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="159"></ref-count>
<page-count count="14"></page-count>
<word-count count="12732"></word-count>
</counts>
</article-meta>
</front>
<body>
<p>The Epstein–Barr virus (EBV) is a gamma-herpes family virus that infects most of humans with a marked tropism for B lymphocytes. EBV is an oncogenic virus known to be the causative agent of several types of neoplasms, including B, T, and NK cell lymphomas, nasopharyngeal and gastric carcinomas, and Epstein–Barr virus-associated smooth muscle tumors (EBV-SMT). 110,000–200,000 cancer cases per year are attributable to EBV worldwide (<xref ref-type="bibr" rid="B1">1</xref>).</p>
<p>The reservoir of EBV is strictly human. After the age of 35 years, the incidence of the infection in the general population is more than 90%. The primary infection occurs in the oropharynx where EBV virions infect epithelial cells and B lymphocytes <italic>via</italic> the CD21 molecule. During the primary infection, EBV drives the activation and the expansion of latently infected B lymphoblasts (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B3">3</xref>). These proliferating B cells express EBV latent growth-transforming genes that establish EBV persistence (latency III program) and are mainly eliminated by specific CD8<sup>+</sup> T cells that strongly expand during the immune response. Innate cytotoxic lymphocytes like NK cells, γδ T cells, and iNKT cells, specifically early differentiated KIR-negative NK cells and Vγ9Vδ2 T cells, are also thought to play an important role in the early phase of the primary infection by recognition of lytically and latently EBV-replicating cells, respectively (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>). Some EBV-infected B cells escape to the immune response by downregulating latent genes expression (latency 0 program) and acquire a memory phenotype, becoming invisible to the immune system and establishing a reservoir for EBV. Subsequent stimulations of these EBV-containing “reservoir” memory B cells will lead to reactivation of EBV from latency into the lytic cycle, thus promoting infections of new B cells and their expansion. Ultimately, EBV-transformed lymphoblasts can lead to lymphoma. In some very rare cases, EBV can also infect T cells and NK cells. This peculiar profile of infection is rather observed in Asian and South American populations and is associated with a chronic viremia, infiltration of organs with by EBV-positive lymphocytes, and life-threatening lymphoproliferative disorders (LPDs) including hemophagocytic syndrome or/and EBV-positive T/NK cell lymphoma. The mechanisms underlying the pathogenesis of this infection are not clearly known, as well as its genetic determinants that are thought to be oligogenic or polygenic (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>). This unusual EBV infection will not be covered in this review.</p>
<p>The first encounter with EBV usually happens during infancy and adolescence by oral transmission and is largely asymptomatic. However, in some immunocompetent individuals particularly during adolescence, primary infection causes infectious mononucleosis (IM), a self-limiting lymphoproliferative disease clinically characterized by fever, sore throat, body aches, swollen lymph nodes, and general fatigue (<xref ref-type="bibr" rid="B3">3</xref>). The lymphoproliferation consists of a robust and sustained expansion of CD8<sup>+</sup> T cells and infected B cells reflecting a strong immune response to the virus. Notably, CD8<sup>+</sup> EBV-specific T cells can represent more than 40% of circulating T cells in some subjects (<xref ref-type="bibr" rid="B8">8</xref>).</p>
<p>In immunocompromised individuals, reactivations of EBV and persistence of proliferating latent growth-transforming EBV-infected B cells are associated with severe pathologies that can have fatal outcome. Those include hemophagocytic lymphohistiocytosis (HLH), also termed virus-associated hemophagocytic syndrome, non-malignant B-cell LPDs, and B-cell lymphomas including Hodgkin’s lymphomas and non-Hodgkin’s lymphomas such as Burkitt’s lymphoma and diffuse large B-cell lymphoma (DLBCL) (<xref ref-type="bibr" rid="B1">1</xref>). Such disorders defined as posttransplant lymproliferative disorders are often observed in patients with organ transplantation under immunosuppressive treatment. Similarly, HIV-infected patients with acquired immunodeficiency syndrome (AIDS) often experience lymphoproliferation disorders driven by EBV, that represent one of the most frequent cause of death in patients with AIDS (<xref ref-type="bibr" rid="B9">9</xref>). Those observations highlight that reactivations of EBV from latently EBV-infected B cells occur frequently in normal individuals throughout life and need to be tightly controlled by the adaptative immune response.</p>
<p>Beside acquired forms, several inherited combined immunodeficiencies (CIDs) leading to a particular susceptibility to EBV infection and to develop EBV-driven diseases have been identified over the last 20 years (<xref ref-type="bibr" rid="B10">10</xref>–<xref ref-type="bibr" rid="B12">12</xref>). Those genetic defects include mutations in <italic>SH2D1A, ITK, MAGT1, CTPS1, CD27, CD70, CORO1A</italic>, and <italic>RASGRP1</italic> (Table <xref ref-type="table" rid="T1">1</xref>). In these genetically determined forms, the penetrance of the EBV susceptibility is high with more than 50% patients having presented at least one severe episode of EBV-driven LPD including Hodgkin and non-Hodgkin lymphomas (Table <xref ref-type="table" rid="T2">2</xref>). However, a number of carriers of these gene defects can also experience other severe viral infections caused by CMV, VZV, HSV, HHV-6, or HPV. This is particularly true for CTPS1 and CORO1A deficiencies since patients often presented VZV and HPV infections, respectively. Bacterial infections, in particular recurrent lung infections are noticed in a number of patients and can be the initial clinical presentation. This may be related to the hypogammaglobulinemia and/or dysgammaglobulinemia associated with low number of CD27<sup>+</sup> memory B cells that are frequently observed in these defects. These phenotypes likely result or have been proven to result from abnormalities in T-cell help to B cells due to defects in T-helper cell maturation and/or activation. Intrinsic defects in B cell development and function may also contribute directly to the hypo/dysgammaglobulinemia, like in RASGRP1, CTPS1, CD27 deficiencies, for which there is clear evidence that these genes are directly involved in B-cell development and/or function. However, these B-cell defects do not to interfere with the ability to EBV to infect B cells and its oncogenic activity. CD4<sup>+</sup> T cell lymphopenia and/or decrease naïve T cells is also a frequent phenotype, which can be considered as an immunological hallmark of a T-cell defect (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B14">14</xref>). NK cells and iNKT cells are also often found to be diminished or absent. Finally, several of these deficiencies are associated with very unique features, independently of the high risk to develop EBV-driven lymphoproliferations, helping to the diagnosis, such as autoimmunity, inflammatory bowel disease (IBD), lung involvement, and neurological disorders that develop in RASGRP1, XIAP-, ITK-, and CORO1A-deficiency, respectively (Table <xref ref-type="table" rid="T1">1</xref>).</p>
<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption>
<p>Lymphoma subtypes in primary immunodeficiencies associated with high susceptibility to develop EBV-driven lymphoproliferative diseases.</p>
</caption>
<table frame="hsides" rules="rows">
<thead>
<tr>
<th align="left" colspan="1" rowspan="2" valign="top">Mutated gene number of patients (<italic>n</italic>)</th>
<th align="center" colspan="1" rowspan="2" valign="top">Age of onset (years)</th>
<th align="left" colspan="1" rowspan="2" valign="top">EBV-associated diseases</th>
<th align="center" colspan="2" rowspan="2" valign="top">Infections</th>
<th align="left" colspan="1" rowspan="2" valign="top">Other clinical features</th>
<th align="center" colspan="3" rowspan="1" valign="top">Immunological features</th>
<th align="left" colspan="1" rowspan="2" valign="top">Outcome</th>
<th align="left" colspan="1" rowspan="2" valign="top">Defective pathways/functions</th>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">T-cells</th>
<th align="left" colspan="1" rowspan="1" valign="top">B-cells</th>
<th align="left" colspan="1" rowspan="1" valign="top">NK-cells</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><bold>SH2D1A (XLP-1)</bold><break></break><italic>n</italic> &gt; 100</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.5–40</td>
<td align="left" colspan="1" rowspan="1" valign="top">SIM/HLH 50–60% (neurological inv. 25%)<break></break>B lymphoma 25–30%<break></break>Vasculitis 3–4%</td>
<td align="left" colspan="1" rowspan="1" valign="top"><bold>EBV 60–70%</bold><break></break>HHV-6 (1)<break></break>HHV-7 (1)<break></break>LCMV (1)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Lung infections 15%<break></break>Diss. aspergillosis (1)<break></break><italic>E. coli</italic> sepsis (1)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Aplastic anemia 3–4%<break></break>EBV-negative lymphoma<break></break>EBV-negative vasculitis</td>
<td align="left" colspan="1" rowspan="1" valign="top">Absence iNKT</td>
<td align="left" colspan="1" rowspan="1" valign="top">Dys-γ, hypo-γ 50%</td>
<td align="left" colspan="1" rowspan="1" valign="top">↓ NK</td>
<td align="left" colspan="1" rowspan="1" valign="top">HSCT 10–40%<break></break>Mortality 20–50%</td>
<td align="left" colspan="1" rowspan="1" valign="top">SLAMR/SAP pathway (T and NK cytotoxicity and AICD)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><bold>XIAP (XLP-2)</bold><break></break><italic>n</italic> &gt; 100</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.5–40</td>
<td align="left" colspan="1" rowspan="1" valign="top">SIM/HLH 50%</td>
<td align="left" colspan="1" rowspan="1" valign="top"><bold>EBV 35–40%</bold><break></break>CMV 10–20%<break></break>HHV-6 (1)</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">IBD 25–40%<break></break>Inflammatory disorders 5% (uveitis, skin abcesses, etc.)<break></break>Cholangitis 1–2%</td>
<td align="left" colspan="1" rowspan="1" valign="top">↓ MAIT<break></break>↓ iNKT</td>
<td align="left" colspan="1" rowspan="1" valign="top">Hypo-γ 15–20%</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">HSCT 10–30%<break></break>Mortality 5–30%</td>
<td align="left" colspan="1" rowspan="1" valign="top">Excess of apoptosis (AICD, TRAIL-R, Fas)<break></break>NOD1/2 signaling/function</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><bold>ITK</bold><break></break><italic>n</italic> = 13</td>
<td align="center" colspan="1" rowspan="1" valign="top">2.5–18</td>
<td align="left" colspan="1" rowspan="1" valign="top">LPD/B lymphoma 13/13<break></break>HLH 1/13<break></break>SMT 1/13</td>
<td align="left" colspan="1" rowspan="1" valign="top"><bold>EBV 13/13</bold><break></break>CMV 1/13<break></break>VZV 1/13<break></break>BK-virus 2/13</td>
<td align="left" colspan="1" rowspan="1" valign="top">Lung infections 9/13<break></break>PCP 2/13</td>
<td align="left" colspan="1" rowspan="1" valign="top">Lung involvement 11/13<break></break>Kidney involvement 3/13<break></break>Al cytopenias 3/13</td>
<td align="left" colspan="1" rowspan="1" valign="top">↓ CD4<sup>+</sup> 8/13<break></break>↓ iNKT 5/5</td>
<td align="left" colspan="1" rowspan="1" valign="top">Hypo-γ 8/13</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">HSCT 4/13<break></break>Death 7/13</td>
<td align="left" colspan="1" rowspan="1" valign="top">TCR induced calcium flux<break></break>T-cell proliferation</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><bold>MAGT1</bold><break></break><italic>n</italic> = 11</td>
<td align="center" colspan="1" rowspan="1" valign="top">3–45</td>
<td align="left" colspan="1" rowspan="1" valign="top">LPD/B lymphoma 7/11</td>
<td align="left" colspan="1" rowspan="1" valign="top"><bold>EBV 11/11</bold><break></break>HSV 2/11, VZV 1/11<break></break>JC virus (PML) 1/11<break></break>HHV-8 (KS) 1/11</td>
<td align="left" colspan="1" rowspan="1" valign="top">Lung infections 9/11</td>
<td align="left" colspan="1" rowspan="1" valign="top">Al cytopenias 3/11</td>
<td align="left" colspan="1" rowspan="1" valign="top">↓ CD4<sup>+</sup><break></break>↓ NKG2D</td>
<td align="left" colspan="1" rowspan="1" valign="top">Dys-γ, hypo-γ 8/11<break></break>Lymphocytosis</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">HSCT 2/11<break></break>Death 3/11</td>
<td align="left" colspan="1" rowspan="1" valign="top">NKG2D-dependent cytotoxicity</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><bold>CORO1A</bold><break></break><italic>n</italic> = 9</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.5–7</td>
<td align="left" colspan="1" rowspan="1" valign="top">LPD/B lymphoma 5/9</td>
<td align="left" colspan="1" rowspan="1" valign="top"><bold>EBV 5/9</bold><break></break>HPV 4/9, VZV 5/9<break></break>HSV 2/9<break></break>Parvovirus B19 1/9</td>
<td align="left" colspan="1" rowspan="1" valign="top">Lung infections 7/9<break></break>Cutaneous leprosy 1/9<break></break>Visceral leishmaniasis 1/9</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neurological involvement (cognitive impairment) 3/9</td>
<td align="left" colspan="1" rowspan="1" valign="top">↓ CD4<sup>+</sup> 8/9<break></break>↓ MAIT 1/1<break></break>↓ iNKT 1/1</td>
<td align="left" colspan="1" rowspan="1" valign="top">High IgE level 4/5</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">HSCT 2/9<break></break>Death 4/9</td>
<td align="left" colspan="1" rowspan="1" valign="top">Actin regulation<break></break>T-cell survival<break></break>NK cytotoxicity</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><bold>CD27</bold><break></break><italic>n</italic> = 18</td>
<td align="center" colspan="1" rowspan="1" valign="top">1–22</td>
<td align="left" colspan="1" rowspan="1" valign="top">LPD/B lymphoma 12/18<break></break>T-cell lymphoma 1/18<break></break>SIM/HLH 5/18<break></break>Meningitis 1/18</td>
<td align="left" colspan="1" rowspan="1" valign="top"><bold>EBV 18/18</bold><break></break>VZV 2/18<break></break>CMV 1/18</td>
<td align="left" colspan="1" rowspan="1" valign="top">Lung infections 4/18<break></break>Gram-positive sepsis 1/18<break></break>Giardiasis 1/18</td>
<td align="left" colspan="1" rowspan="1" valign="top">Aplastic anemia 1/18<break></break>Uveitis 5/18<break></break>Oral anal ulcers 5/18</td>
<td align="left" colspan="1" rowspan="1" valign="top">↓ iNKT 3/10</td>
<td align="left" colspan="1" rowspan="1" valign="top">Hypo-γ 13/18</td>
<td align="left" colspan="1" rowspan="1" valign="top">↓ NK</td>
<td align="left" colspan="1" rowspan="1" valign="top">HSCT 4/18<break></break>Death 3/18</td>
<td align="left" colspan="1" rowspan="1" valign="top">CD27–CD70 pathway (T-cell proliferation)<break></break>NK cytotoxicity</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><bold>CTPS1</bold><break></break><italic>n</italic> = 12</td>
<td align="center" colspan="1" rowspan="1" valign="top">0–5</td>
<td align="left" colspan="1" rowspan="1" valign="top">LPD/B lymphoma 5/12<break></break>SIM 5/12</td>
<td align="left" colspan="1" rowspan="1" valign="top"><bold>EBV 11/12</bold><break></break>VZV 6/12<break></break>Norovirus 3/12<break></break>CMV 2/12, HHV-6 2/12</td>
<td align="left" colspan="1" rowspan="1" valign="top">Lung infections 7/12<break></break>Meningitis 3/12</td>
<td align="left" colspan="1" rowspan="1" valign="top">Eczema 2/12</td>
<td align="left" colspan="1" rowspan="1" valign="top">↓ MAIT<break></break>↓ iNKT</td>
<td align="left" colspan="1" rowspan="1" valign="top">↓ lgG2 5/5<break></break>↓ CD27<sup>+</sup> B-cells</td>
<td align="left" colspan="1" rowspan="1" valign="top">↓ NK</td>
<td align="left" colspan="1" rowspan="1" valign="top">HSCT 9/12<break></break>Death 3/12</td>
<td align="left" colspan="1" rowspan="1" valign="top"><italic>De novo</italic> pyrimidine synthesis<break></break>T- and B-cell proliferation</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><bold>RASGRP1</bold><break></break><italic>n</italic> = 6</td>
<td align="center" colspan="1" rowspan="1" valign="top">5–12</td>
<td align="left" colspan="1" rowspan="1" valign="top">LPD/B lymphoma 4/6<break></break>SMT 2/6</td>
<td align="left" colspan="1" rowspan="1" valign="top"><bold>EBV 5/6</bold><break></break>HSV 1/6<break></break>HPV (EV) 1/6<break></break>CMV 1/6</td>
<td align="left" colspan="1" rowspan="1" valign="top">Lung infections 5/6<break></break>Diss. tuberculosis 1/6<break></break>LN tuberculosis 1/6<break></break>PCP 1/6</td>
<td align="left" colspan="1" rowspan="1" valign="top">Al cytopenias 3/6<break></break>EBV-negative<break></break>LPD 2/6</td>
<td align="left" colspan="1" rowspan="1" valign="top">↓ CD4<sup>+</sup> 4/6<break></break>↓ MAIT 2/2<break></break>↓ iNKT 2/2</td>
<td align="left" colspan="1" rowspan="1" valign="top">Hypo-γ 1/6<break></break>Hyper-γ 2/6<break></break>↓ CD27<sup>+</sup> B-cells 2/4</td>
<td align="left" colspan="1" rowspan="1" valign="top">↓ NK 3/6</td>
<td align="left" colspan="1" rowspan="1" valign="top">HSCT 2/6<break></break>Death 2/6</td>
<td align="left" colspan="1" rowspan="1" valign="top">MAPK pathway (ERK1/2, T-, B-cell proliferation)<break></break>Actin/cytoskeleton dynamics<break></break>NK cytotoxicity</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">CD70<break></break><italic>n</italic> = 6</td>
<td align="center" colspan="1" rowspan="1" valign="top">1–5</td>
<td align="left" colspan="1" rowspan="1" valign="top">LPD/B-cell lymphoma 5/6</td>
<td align="left" colspan="1" rowspan="1" valign="top">EBV 6/6<break></break>VZV 1/6</td>
<td align="left" colspan="1" rowspan="1" valign="top">Lung infections 3/6</td>
<td align="left" colspan="1" rowspan="1" valign="top">PFAPA 1/6<break></break>Hypersensitivity to mosquito bites 1/6</td>
<td align="left" colspan="1" rowspan="1" valign="top">↓ MAIT 1/1<break></break>↓ iNKT 1/1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Hypo-γ 5/6<break></break>↓ CD27<sup>+</sup> B-cells 3/6</td>
<td align="left" colspan="1" rowspan="1" valign="top">HSCT 1/6<break></break>All alive</td>
<td align="left" colspan="1" rowspan="1" valign="top">CD27–CD70 pathway (T-cell proliferation)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decreased 2B4 and NKG2D on memory T CD8<sup>+</sup></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>SIM, severe infectious mononucleosis; HLH, hemophagocytic lymphohistiocytosis; LPD, lymphoproliferative disorder; inv., involvement; Diss., disseminated; PCP, pneumocytosis pneumoniae; IBD, inflammatory bowel disease; Al, autoimmunity; Dys-γ, dysgammaglobulinemia; Hypo-γ, hypogammaglobulinemia; KS, Kaposi sarcoma; PFAPA, perdiodic fever, aphtous stomatitis, pharyngitis and cervical adenitis; EV, epidermodysplasia verruciformis; SMT, smooth muscle tumor; PML, progressive multifocal leukoencephalopathy; HSCT, hematopoietic stem cell transplantation; LN, lymph node; EBV, Epstein–Barr virus; LCMV, lymphocytic choriomeningitis virus; CMV, cytomegalovirus; HHV, human herpes virus; VZV, varicella zoster virus; MAIT, mucosal-associated invariant T; AICD, activation-induced cell death; TCR, T-cell receptor; SAP, SLAM-associated protein; SLAMR, SLAM receptor</italic>.</p>
</table-wrap-foot>
</table-wrap>
<table-wrap id="T2" position="float">
<label>Table 2</label>
<caption>
<p>Lymphoma subtypes in primary immunodeficiencies associated with high susceptibility to develop EBV-driven lymphoproliferative diseases.</p>
</caption>
<table frame="hsides" rules="rows">
<thead>
<tr>
<th align="left" colspan="1" rowspan="2" valign="top">Mutated gene number of patients/total</th>
<th align="left" colspan="1" rowspan="2" valign="top">Hodgkin lymphoma (subtype)</th>
<th align="center" colspan="3" rowspan="1" valign="top">B-cell NHL</th>
<th align="left" colspan="1" rowspan="2" valign="top">T-cell lymphoma</th>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">DLBCL</th>
<th align="left" colspan="1" rowspan="1" valign="top">Burkitt lymphoma</th>
<th align="left" colspan="1" rowspan="1" valign="top">Not specified</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><bold>SH2D1A</bold><break></break>25–30%</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">30–40%: abdominal<break></break>(40–50%), cervical<break></break>(30–40%), spinal<break></break>(10–20%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">40–60%: abominal<break></break>(50–60%), cervical<break></break>(20%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">20–30%</td>
<td align="left" colspan="1" rowspan="1" valign="top">1 patient (CNS)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><bold>ITK</bold><break></break>9/13</td>
<td align="left" colspan="1" rowspan="1" valign="top">6 patients (1 mixed cellularity)</td>
<td align="left" colspan="1" rowspan="1" valign="top">1 patient</td>
<td align="left" colspan="1" rowspan="1" valign="top">1 patient</td>
<td align="left" colspan="1" rowspan="1" valign="top">1 patient</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><bold>MAGT1</bold><break></break>5/11</td>
<td align="left" colspan="1" rowspan="1" valign="top">2 patients</td>
<td align="left" colspan="1" rowspan="1" valign="top">1 patient</td>
<td align="left" colspan="1" rowspan="1" valign="top">1 patient</td>
<td align="left" colspan="1" rowspan="1" valign="top">1 patient</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><bold>COR01A</bold><break></break>4/9</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">4 patients</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><bold>CD27</bold><break></break>6/18</td>
<td align="left" colspan="1" rowspan="1" valign="top">3 patients (2 scleronodular and 1 mixed cellularity)</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">2 patients</td>
<td align="left" colspan="1" rowspan="1" valign="top">1 patient</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><bold>CTPS1</bold><break></break>2/12</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">2 patients<break></break>(CNS 2/2)</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><bold>RASGRP1</bold><break></break>4/6</td>
<td align="left" colspan="1" rowspan="1" valign="top">2 patients (1 scleronodular and 1 mixed cellularity)</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top">2 patients</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><bold>CD70</bold><break></break>4/6</td>
<td align="left" colspan="1" rowspan="1" valign="top">4 patients (1 scleronodular and 1 mixed cellularity)</td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
<td align="left" colspan="1" rowspan="1" valign="top"></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>CNS, central nervous system; NHL, non-Hodgkin lymphoma; DLBCL, diffuse large B-cell lymphoma; EBV, Epstein–Barr virus</italic>.</p>
</table-wrap-foot>
</table-wrap>
<p>Over the last two decades, these inherited defects have represented very unique <italic>in natura</italic> models to decipher the immune response to EBV. Molecular and genetic characterization of these disorders and their study have revealed several unexpected and novel pathways required for an efficient immunity to EBV, but also more generally involved in cancer immune surveillance of B lymphocytes, and adaptative immune responses.</p>
<sec id="S1">
<title>SH2D1A/SLAM-Associated Protein (SAP) Deficiency</title>
<p>SH2D1A/SAP deficiency (also known as the X-linked lymphoproliferative syndrome type 1-XLP-1 or Purtilo syndrome) is caused by hemizygous mutations in the X-linked gene <italic>SH2D1A</italic> (<xref ref-type="bibr" rid="B15">15</xref>–<xref ref-type="bibr" rid="B19">19</xref>). More than 100 patients with hemizygous deleterious mutations in <italic>SH2D1A</italic> have been reported, but if considering the literature before the discovery of the gene, this is probably more than 200 cases (<xref ref-type="bibr" rid="B20">20</xref>–<xref ref-type="bibr" rid="B22">22</xref>). Clinical features of XLP-1 are EBV-driven fulminant or severe mononucleosis with all the clinical features of HLH including fulminant hepatitis, hepatic necrosis, bone marrow hypoplasia, neurological involvement in 20–30% of cases, hypogammaglobulinemia (50%), and B-cell lymphoma (25–30%) which often have abdominal localization. Few other rare phenotypes can be also observed such as vasculitis (2–5%), aplastic anemia (2–5%), and chronic gastritis (<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B23">23</xref>–<xref ref-type="bibr" rid="B26">26</xref>). All phenotypes can occur independently and some develop without any evidence of EBV infection (10–20%) or prior to EBV infection like HLH, hypogammaglobulinemia, lymphoma, aplastic anemia, and vasculitis (<xref ref-type="bibr" rid="B24">24</xref>–<xref ref-type="bibr" rid="B26">26</xref>). Some rare cases of T-cell lymphoma have also been reported (<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B27">27</xref>). However, a significant proportion of patients initially presented with combined variable immunodeficiency (CVID) associated with severe recurrent bacterial infections including disseminated aspergillosis and <italic>E. coli</italic> sepsis (<xref ref-type="bibr" rid="B28">28</xref>–<xref ref-type="bibr" rid="B31">31</xref>). Only five cases of other severe viral infections by HHV-6, HHV-7, and LCMV or HLH without EBV trigger have been reported in the recent literature (<xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B33">33</xref>). This highlights that SAP has a very unique role in immunity to EBV, when it is not required for other viral infections except in very rare cases.</p>
<p><italic>SH2D1A</italic> encodes a small adaptor protein of 128 amino acids named SAP, uniquely expressed in T and NK cells. SAP is only made of a unique SH2 domain that specifically binds to the intracytoplasmic domain of receptors of the SLAM family (SLAMF), which are self-ligands and are involved in homotypic cell–cell interactions with the exception of 2B4 (also known as CD244 or SLAMF4) that binds CD48 (<xref ref-type="bibr" rid="B34">34</xref>–<xref ref-type="bibr" rid="B36">36</xref>). On the one hand, SAP functions as a real adapter protein by its ability to recruit the tyrosine kinase FynT to SLAMF receptors, thus coupling those to downstream signaling pathways. On the other hand, SAP acts also as a blocker protein by inhibiting the recruitment of SH2-containing phosphatases to SLAMF (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B37">37</xref>–<xref ref-type="bibr" rid="B39">39</xref>). Early studies have documented NK-cell cytotoxicity defects toward EBV-infected B cells in XLP-1 patients (<xref ref-type="bibr" rid="B40">40</xref>, <xref ref-type="bibr" rid="B41">41</xref>). Further investigations revealed that these defects involved two SLAM receptors, 2B4 and SLAMF6 (also known as NTB-A or Ly108) which have the capacity to trigger and activate NK- and CD8<sup>+</sup> T-cell cytotoxicity toward EBV-infected B cells or transformed B cells when SAP is normally expressed (<xref ref-type="bibr" rid="B42">42</xref>–<xref ref-type="bibr" rid="B46">46</xref>). B-cell lymphomas and EBV-infected B cells are known to express high levels of ligands for SLAMF-R, including CD48 the ligand of 2B4 (<xref ref-type="bibr" rid="B47">47</xref>). This expression might signal abnormal “dangerous” proliferating B cells to NK cells and T lymphocytes. Following studies demonstrated that the stimulatory function of 2B4 and SLAMF6, which is dependent of FynT was not only lost in the absence of SAP but also shifted toward an inhibition of other stimulatory pathways of cell cytotoxicity in NK- and CD8<sup>+</sup> T-cells (<xref ref-type="bibr" rid="B43">43</xref>, <xref ref-type="bibr" rid="B48">48</xref>, <xref ref-type="bibr" rid="B49">49</xref>). Additional findings in mice indicated that this inhibitory effect was independent of FynT, but depends of the blocking activity of SAP, and leads to decreased conjugate formation between CD8<sup>+</sup> T or NK cells and SLAMF-expressing target cells like B cells (<xref ref-type="bibr" rid="B50">50</xref>, <xref ref-type="bibr" rid="B51">51</xref>). In this context, other activation pathways of cytotoxicity such as NKG2D may not compensate for the defective function of 2B4 and SLAMF6. The inhibitory activity of 2B4 and SLAMF6 in the absence of SAP may have a trans-inhibitory effect on activating receptors (such as NKG2D and/or killer cell activating receptors) when co-engaged at the cytotoxic synapse.</p>
<p>Importantly, NK-cell and CD8<sup>+</sup> T-cell cytotoxicity toward other APCs or target cells than B cells including non-hematopoietic cells or/and SLAMF-negative target cells was preserved, and even augmented for NK-cell cytotoxicity (<xref ref-type="bibr" rid="B47">47</xref>, <xref ref-type="bibr" rid="B52">52</xref>, <xref ref-type="bibr" rid="B53">53</xref>). Recent studies in mice indicate that this excessive NK-cell cytotoxicity is dependent of a role of SAP and SLAMF6 in NK cell licensing/education (<xref ref-type="bibr" rid="B52">52</xref>). In the absence of SAP, NK-cell responsiveness toward SLAM-negative cells is increased. In XLP-1 patients, increased NK cytotoxicity toward the SLAMF-negative target cells K562 was documented (<xref ref-type="bibr" rid="B54">54</xref>), associated with increased CD16- and NKp46-dependent cytotoxicity (<xref ref-type="bibr" rid="B52">52</xref>). Thus, extra-hematopoietic manifestations associated with HLH seen in XLP-1 patients, like extensive liver damage may be caused by this increased NK-cell cytotoxicity toward non-hematopoietic cells.</p>
<p>Beside its function in NK- and CD8<sup>+</sup> T cell-cytotoxicity, SAP is also important to limit CD8<sup>+</sup> T-cell expansion. SAP-deficient T cells both in mice and human exhibited increased survival due to impaired activation-induced cell death (AICD), an important pathway involves in the contraction of the pool of Ag-specific T-cells during immune responses (<xref ref-type="bibr" rid="B55">55</xref>, <xref ref-type="bibr" rid="B56">56</xref>). The positive role of SAP on AICD is dependent of SLAMF6 that delivers signals for the expression of the pro-apoptotic molecules Bim and FasL (<xref ref-type="bibr" rid="B55">55</xref>). In concert, these distinct defects certainly contribute to the inability of EBV-specific T cells to eliminate EBV-infected B cells and to their uncontrolled expansion and activity during primary infection leading to fulminant mononucleosis or HLH. The fact that patients also frequently develop non-EBV B cell lymphoma argues for an important role of the SLAM–SAP pathway in the immune surveillance of B cells.</p>
</sec>
<sec id="S2">
<title>XIAP Deficiency</title>
<p>XIAP deficiency (also known as the X-linked lymphoproliferative syndrome type 2/XLP-2) is caused by hemizygous mutations in the <italic>XIAP</italic> gene coding the X-linked Inhibitor of Apoptosis Protein XIAP (<xref ref-type="bibr" rid="B54">54</xref>, <xref ref-type="bibr" rid="B57">57</xref>). XIAP is an anti-apoptotic molecule member of the inhibitor of apoptosis protein family (IAP). XIAP is a potent inhibitor of program cell death, but it is also required for the function of (NOD)-like pattern recognition receptors (NLRs) NOD 1 and 2 and the regulation of the inflammasome activity of NLRP3 (<xref ref-type="bibr" rid="B58">58</xref>–<xref ref-type="bibr" rid="B61">61</xref>). More than 100 patients have been now reported with a XIAP deficiency. Initially reported in 2006 in a cohort of patients with a clinical phenotype close to that of SH2D1A-deficient patients (XLP-1), XIAP deficiency was further denominated XLP-2, since <italic>XIAP</italic> is located in the immediate vicinity of <italic>SH2D1A</italic> on the X chromosome (<xref ref-type="bibr" rid="B57">57</xref>). However, during the last 10 years, there were cumulative observations that the two diseases differ by many aspects, in particular, there is no evidence that they are functionally related. The main clinical phenotypes of the XIAP deficiency are the susceptibility to develop HLH in the context of EBV infection (36%), the recurrent splenomegaly corresponding to a minimal form of HLH (57%), and the IBD (26%) with features of Crohn’s disease (<xref ref-type="bibr" rid="B57">57</xref>, <xref ref-type="bibr" rid="B62">62</xref>, <xref ref-type="bibr" rid="B63">63</xref>). The HLH is often less severe than in the XLP-1 deficiency with very rare neurological involvement (<xref ref-type="bibr" rid="B24">24</xref>). Some patients also developed variable auto-inflammatory symptoms like uveitis, arthritis, skin abscesses, erythema nodosum, and nephritis (<xref ref-type="bibr" rid="B62">62</xref>, <xref ref-type="bibr" rid="B63">63</xref>). Thus, today although the susceptibility to EBV remains one important and severe clinical manifestation of the XIAP deficiency, more than half of the patients never experienced a peculiar EBV susceptibility (<xref ref-type="bibr" rid="B57">57</xref>, <xref ref-type="bibr" rid="B62">62</xref>). XIAP-deficient patients also never experience lymphoma in contrast to patients with SAP deficiency, likely related to the anti-apoptotic function of XIAP, which may protect patients from cancer, and XIAP is now considered as a promising therapeutic target for cancer treatment (<xref ref-type="bibr" rid="B64">64</xref>).</p>
<p>T lymphocytes from XLP-2 patients have been shown to exhibit increased AICD in response to T-cell receptor (TCR) activation and increased apoptosis to FAS/CD95 and TRAIL-R stimulations (<xref ref-type="bibr" rid="B54">54</xref>). On the other hand, monocytes from patients displayed impaired production of cytokines and chemokines (TNF-α, IL-10, IL-8, and MCP-1) to stimulation with NOD2 ligands (<xref ref-type="bibr" rid="B63">63</xref>, <xref ref-type="bibr" rid="B65">65</xref>). Although the mechanisms of EBV-driven HLH in XIAP deficiency remains unclear, it is proposed that excessive AICD might compromise the expansion and proliferation of activated EBV-specific T cells like in CTPS1, CD27, or CD70 deficiencies (see below)(<xref ref-type="bibr" rid="B58">58</xref>). In this setting, accumulation of apoptotic cells and persistence of EBV-infected B cells could result in abnormal inflammation amplified by impaired inflammasome regulation and/or defective NOD1/2 activation of myeloid cell populations. In concert, T lymphocytes and myeloid defects may contribute to EBV-driven HLH in XIAP-deficient patients.</p>
</sec>
<sec id="S3">
<title>ITK Deficiency</title>
<p>ITK deficiency is an autosomal recessive disorder caused by bi-allelic mutations in <italic>ITK</italic>. Until now, 13 patients from 8 families have been reported in the literature (<xref ref-type="bibr" rid="B66">66</xref>–<xref ref-type="bibr" rid="B72">72</xref>). All experienced EBV-associated recurrent non-malignant LPD or malignant B-cell lymphoproliferations including Hodgkin lymphoma in five, and one develop an EBV-SMT (<xref ref-type="bibr" rid="B69">69</xref>). B-cell lymphoproliferations have often a pulmonary localization and more than 50% also develop pulmonary infections. ITK (IL-2-inducible tyrosine kinase) is a well-characterized protein tyrosine kinase of the TEC/BTK family specifically expressed in T lymphocytes and NK cells. ITK is involved in TCR signaling by its capacity to phosphorylate and activate the PLC-γ1, a key enzyme that stimulates Ca<sup>++</sup> fluxes through the production of IP3, both being critical second messengers of T-cell activation (<xref ref-type="bibr" rid="B73">73</xref>, <xref ref-type="bibr" rid="B74">74</xref>). ITK has been also involved in CXCR4 signaling (<xref ref-type="bibr" rid="B75">75</xref>). Mice studies demonstrated the importance of ITK in immunity particularly in CD4<sup>+</sup> T-cell responses (<xref ref-type="bibr" rid="B73">73</xref>, <xref ref-type="bibr" rid="B76">76</xref>). A recent report showed that ITK is also required for efficient CD8<sup>+</sup> T-cell responses in mouse (<xref ref-type="bibr" rid="B77">77</xref>). In the absence of ITK, CD8<sup>+</sup> T-cell expansion and maturation into cytolytic effector T cells is impaired leading to decreased CD8<sup>+</sup> T-cell cytotoxic responses. Very few studies have been made to characterize ITK-deficient T cells from patients, albeit-derived T-cell lines from ITK-deficient patients have been obtained and studied showing decreased Ca<sup>++</sup> mobilization (<xref ref-type="bibr" rid="B67">67</xref>). Defective T-cell proliferation in response to TCR engagement was documented in one patient (<xref ref-type="bibr" rid="B69">69</xref>). Although the exact mechanism(s) underlying EBV susceptibility in ITK deficiency need to be established, the recent study of CD8<sup>+</sup> T cells from ITK-deficient mice (<xref ref-type="bibr" rid="B77">77</xref>), strongly supports that in T cells from ITK-deficient patients, TCR activation signals are impaired resulting in defective expansion and maturation of EBV-specific CD8<sup>+</sup> T cells like in CD70 and CD27 deficiencies (see below).</p>
</sec>
<sec id="S4">
<title>MAGT1 Deficiency</title>
<p>MAGT1 deficiency also termed XMEN disease (for X-linked immunodeficiency, magnesium defect, EBV infection, and neoplasia syndrome) is caused by hemizygous mutations in <italic>MAGT1</italic>. To date, 11 male patients with MAGT1 deficiency have been identified and all developed susceptibility to EBV infection with chronic viremia and B-cell lymphomas including Hodgkin and DLBCL (<xref ref-type="bibr" rid="B78">78</xref>–<xref ref-type="bibr" rid="B82">82</xref>). In one patient, the initial clinical presentation was a HHV-8-associated Kaposi sarcoma (<xref ref-type="bibr" rid="B80">80</xref>). One particular trait of this disease is the B-cell lymphocytosis associated with a CD4 lymphopenia (<xref ref-type="bibr" rid="B83">83</xref>). <italic>MAGT1</italic> encodes a ubiquitously expressed transmembrane Mg<sup>++</sup> transporter involved in the maintenance of free basal intracellular Mg<sup>++</sup> pools. However, MAGT1 also associates with the <italic>N</italic>-oligosaccharyl transferase complex, and therefore may have a role in protein N-glycosylation (<xref ref-type="bibr" rid="B84">84</xref>). Following the discovery of the MAGT1 immunodeficiency, MAGT1-dependent Mg<sup>++</sup> influx was documented in T cells upon TCR engagement. Importantly, this Mg<sup>++</sup> mobilization was shown to be involved in PLC-γ1 activation and subsequent dependent Ca<sup>++</sup> influx (<xref ref-type="bibr" rid="B78">78</xref>). Notably, all these events were markedly impaired in activated MAGT1-deficient T cells in response to TCR, but T-cell proliferation has been considered to be normal or diminished (<xref ref-type="bibr" rid="B85">85</xref>). Based on these findings, it was proposed that MAGT1 might be necessary to activate PLC-γ1 possibly by acting on ITK. In a recent study, intriguingly, Ca<sup>++</sup> mobilization was found to be only moderately decreased and delayed in T cells from a patient carrier of a deletion encompassing <italic>MAGT1</italic> (<xref ref-type="bibr" rid="B80">80</xref>). Along these lines, an other recent report showed that MAGT1-deficient T cells from mice exhibited normal calcium flux upon TCR activation, while calcium flux was impaired in B cells in response to BCR stimulation (<xref ref-type="bibr" rid="B86">86</xref>). The discrepancy between these recent observations and earlier studies is not known. In any case, MAGT1 was further shown to be required for expression and function of NKG2D and its signaling adapter DAP10 (<xref ref-type="bibr" rid="B79">79</xref>). NKG2D is an activating NK-cell receptor expressed on NK cells, γδ T cells, and CD8<sup>+</sup> T cells, that recognizes MHC class I-homologous proteins induced by cellular stress in response to infection or neoplasia. Importantly, ligands of NKG2D are upregulated on EBV-infected B cells and EBV-associated lymphoproliferations (<xref ref-type="bibr" rid="B87">87</xref>, <xref ref-type="bibr" rid="B88">88</xref>). Consistent with defective NKG2D expression, MAGT1-deficient CD8<sup>+</sup> T cells displayed impaired cytotoxic activity against autologous EBV-transformed B cells. Importantly, magnesium supplementation treatment <italic>in vivo</italic> and <italic>in vitro</italic> restored basal intracellular Mg<sup>++</sup> concentration, NKG2D expression, cell cytotoxicity, and immunity to EBV in MAGT1-deficient patients (<xref ref-type="bibr" rid="B79">79</xref>). Defective N-glycosylation of NKG2D associated with increased ubiquitinylation leading to accelerated protein turnover might be considered as the main mechanism explaining the impaired NKG2D function. Thus, these observations highlight the essential role of the NKG2D pathway in immunity to EBV, albeit the exact role of MAGT1 in TCR signaling remains to be clarified.</p>
</sec>
<sec id="S5">
<title>CD27 Deficiency</title>
<p>This deficiency is caused by bi-allelic mutations in <italic>CD27</italic> that encodes a protein belonging to the super family of TNF receptors (TNFSFR), also known as TNFSFR7. Until today, 18 patients have been reported and all developed EBV-associated LPDs including malignant B-cell proliferations, Hodgkin’s lymphoma, B lymphoma, and few patients developed HLH triggered by EBV (<xref ref-type="bibr" rid="B89">89</xref>–<xref ref-type="bibr" rid="B92">92</xref>). Some patients also experienced inflammatory symptoms such as uveitis and oral ulcers. CD27 binds to CD70 (also named TNFSF7), a member of the TNF superfamily ligands. CD27 is highly expressed by T cells including resting T cells and a small fraction of B cells corresponding to memory B cells (<xref ref-type="bibr" rid="B93">93</xref>–<xref ref-type="bibr" rid="B95">95</xref>). CD27 is a co-stimulatory molecule of T-cell activation and CD27–CD70 interactions in mice have been shown to enhance T-cell survival, effector functions, and memory T-cell expansion, in particular CD8<sup>+</sup> T cells during anti-viral immune responses (<xref ref-type="bibr" rid="B96">96</xref>, <xref ref-type="bibr" rid="B97">97</xref>). Insights to the mechanism underlying the high susceptibility to EBV in CD27 deficiency was recently given by the identification of CD70-deficient patients (see below).</p>
</sec>
<sec id="S6">
<title>CD70 Deficiency</title>
<p>Five patients with homozygous deleterious mutations in <italic>CD70</italic> have been reported in 2017 and one in 2018 (<xref ref-type="bibr" rid="B91">91</xref>, <xref ref-type="bibr" rid="B98">98</xref>, <xref ref-type="bibr" rid="B99">99</xref>). Five out of six patients developed EBV-Hodgkin’s lymphoma and recurrent B-cell lymphoproliferations, and one initially presented clinical signs evoking a Behçet-like syndrome and had uncharacterized viral encephalitis. All patients had dysgammaglobulinemia and two patients developed other infections. By many aspects CD70-deficiency appears to be a phenocopy of the CD27 deficiency. In peripheral blood mononuclear cells, CD70 is only expressed by a very small fraction of B cells (<xref ref-type="bibr" rid="B91">91</xref>), but its expression is strongly upregulated on activated B cells and EBV-infected B cells during primary infection in tonsils of patients with IM (<xref ref-type="bibr" rid="B91">91</xref>). B-cell lymphomas and several other cancers such as solid carcinomas are also known to express CD70 (<xref ref-type="bibr" rid="B94">94</xref>). Izawa et al. demonstrated that CD70 expression on EBV-infected B cells drives the expansion of EBV-specific cytolytic T cells <italic>via</italic> a TCR-CD27-dependent co-stimulation. When CD70 is absent on EBV-infected B cells, or CD27 on T cells, EBV-specific T cells failed to expand leading to reduced cytotoxicity responses toward EBV-infected B cells (<xref ref-type="bibr" rid="B91">91</xref>). Decreased expression of 2B4 and NKG2D on memory CD8<sup>+</sup> T cells of CD70-deficient patients was also noticed and may also contribute to the inability of T cells to eliminate EBV-infected B cells (<xref ref-type="bibr" rid="B98">98</xref>). These findings demonstrate that the CD70–CD27 axis represents a key component of the protective immunity to EBV. Furthermore, the implication of the CD27–CD70 axis in anti-tumoral immune surveillance of abnormal B cells is supported by the observations that <italic>CD70</italic> is often found somatically mutated in B lymphomas, perhaps to escape to the immune surveillance (<xref ref-type="bibr" rid="B91">91</xref>).</p>
</sec>
<sec id="S7">
<title>CTPS1 Deficiency</title>
<p>CTPS1 deficiency is an autosomal recessive immunodeficiency caused by a unique homozygous deleterious mutation in <italic>CTPS1</italic> with a founder effect in the population of the North West of England. Until now, 12 patients have been reported and all but 1 presented EBV susceptibility including severe infectious mononucleosis, LPD, and B-cell lymphoma, which was the initial clinical presentation in 40% of cases (<xref ref-type="bibr" rid="B100">100</xref>–<xref ref-type="bibr" rid="B102">102</xref>). Half of them also developed other viral infections including CMV, VZV, and HHV-6. Some also experienced recurrent bacterial infections with <italic>Haemophilus influenza, Streptococcus pneumonia</italic>, and/or <italic>Neisseria meningitis</italic>. <italic>CTPS1</italic> codes for the CTP synthetase or synthase 1, a key enzyme of the <italic>de novo</italic> synthesis of the CTP nucleotide, which is the limiting nucleotide in cells (<xref ref-type="bibr" rid="B103">103</xref>). CTP is a critical precursor in the metabolism of nucleic acids. CTP is produced by two pathways, a salvage pathway and a <italic>de novo</italic> synthesis pathway. The salvage pathway utilizes cytidine, a degradation product from nucleic acids. The “<italic>de novo</italic>” CTP synthesis is dependent of two enzymes CTPS1 and CTPS2, which catalyze ATP-dependent amination of UTP to CTP with ammonia (-NH3) transfer from hydrolyzed glutamine. In normal tissues, CTPS activity is rather low, while it is high in proliferating cells like cancer cells including lymphoma. Importantly, CTPS1 is very low in resting T cells and is rapidly and strongly upregulated in response to TCR stimulation (<xref ref-type="bibr" rid="B100">100</xref>). In CTPS1-deficient patients, the proliferation of T cells in response to TCR engagement is markedly impaired, while other T-cell responses including cytokines production, AICD, and cytotoxicity are not affected, and T cells normally proliferate in response to IL-2. Addition of CTP or cytidine in the culture medium restored T-cell proliferation of activated T cells. CTPS1 expression is also upregulated in activated B cells. However, the role of CTPS1 in B cells may be less important than in T cells as patients developed rather infections associated with a T-cell defect and the absence of CTPS1 has no effect on proliferation of EBV-infected B cells and their transformation by EBV. The discovery of the CTPS1 deficiency emphasizes the importance of T-cell expansion during anti-viral responses, specifically in primary infection to EBV, since 40% T cells of circulating can be specific to EBV (<xref ref-type="bibr" rid="B8">8</xref>).</p>
</sec>
<sec id="S8">
<title>CORO1A Deficiency</title>
<p>Deficiency in the actin regulator CORO1A (Coronin-1A) has been identified in nine patients (<xref ref-type="bibr" rid="B104">104</xref>–<xref ref-type="bibr" rid="B108">108</xref>). Patients presented with severe infections, and five developed EBV-driven B cell lymphoma. Four patients had severe mucocutaneous-immunodeficiency manifestations including epidermodysplasia verruciformis-HPV (EV-HPV) (<xref ref-type="bibr" rid="B104">104</xref>, <xref ref-type="bibr" rid="B108">108</xref>). Three patients also exhibited neurological abnormalities including autism-like symptoms. Patients with CORO1A deficiency are characterized by a profound T cell lymphopenia with strongly decreased or nearly absent naïve cells associated with defective thymic output. CORO1A-deficient T cells from patients showed increased spontaneous <italic>in vitro</italic> apoptosis, delayed ERK1/2 activation, increased filamentous actin, but normal or reduced T cell proliferation to mitogens and antigens and normal calcium flux and cytotoxicity. It is proposed that CORO1A deficiency is primarily a T-cell immunodeficiency caused by impaired thymic egress, migration, and survival of mature T cells, thereby affecting lymphocyte homeostasis, repertoire selection, and lineage commitment (<xref ref-type="bibr" rid="B109">109</xref>). CORO1A belongs to the family of Coronins that are evolutionarily conserved intracellular actin-binding proteins expressed at high level in most of leukocyte populations (<xref ref-type="bibr" rid="B110">110</xref>). In T cells, CORO1A has been shown to be a negative regulator of branched F-actin formation and be required for chemokine-mediated migration and lymphocyte survival given the fact that accumulation of F-actin is known to be toxic for cells (<xref ref-type="bibr" rid="B108">108</xref>, <xref ref-type="bibr" rid="B111">111</xref>). However, CORO1A in T cells has been also involved in a variety of pathways including TCR and TGF-β signaling and immunologic synapse (IS) formation (<xref ref-type="bibr" rid="B112">112</xref>–<xref ref-type="bibr" rid="B115">115</xref>). Along these lines, defective NK cell degranulation was reported in one patient in association with increased density of F-actin at the cytotoxic synapse (<xref ref-type="bibr" rid="B113">113</xref>). Neurological abnormalities found in patients are likely explained by the role of coronin-1A in neurodevelopment that has been reported in mice (<xref ref-type="bibr" rid="B116">116</xref>). Finally, Coronin 1A was recently shown to be required for neutrophil trafficking. These observations suggest that the immune defects in patients may not only be restricted to T cells (<xref ref-type="bibr" rid="B117">117</xref>). While it is not clearly established why patients with CORO1A deficiency are susceptible to EBV, it is very likely that the poor T-cell survival may result in defective expansion of EBV-specific CD8<sup>+</sup> T-cells leading to impaired control of EBV-infected B cells. Interestingly, four patients developed EV-HPV, which could bring closer CORO1A deficiency to primary immunodeficiencies (PIDs) associated with frequent and extensive HPV infections, especially those such as MST1/STK4 and DOCK8 deficiencies, that are characterized by CD4 lymphopenia, defective T cell migration, and/or abnormal F-actin polymerization and IS formation (<xref ref-type="bibr" rid="B118">118</xref>).</p>
</sec>
<sec id="S9">
<title>RASGRP1 Deficiency</title>
<p>RASGRP1 deficiency is caused by bi-allelic mutations in <italic>RASGRP1</italic>. So far, three different null homozygous mutations have been identified in four patients having developed severe EBV-driven LPDs including two Hodgkin lymphoma. One had also an EBV-SMT (<xref ref-type="bibr" rid="B119">119</xref>–<xref ref-type="bibr" rid="B121">121</xref>). <italic>RASGRP1</italic> codes for a diacylglycerol-regulated guanidine exchange factor preferentially expressed in T and NK cells (<xref ref-type="bibr" rid="B122">122</xref>, <xref ref-type="bibr" rid="B123">123</xref>), which acts as an activator of the small G protein RAS and the downstream RAF-MEK-ERK kinases cascade (also known as the MAP kinases pathway). In T lymphocytes, RASGRP1 is the main activator of the MAP kinases pathway (<xref ref-type="bibr" rid="B124">124</xref>, <xref ref-type="bibr" rid="B125">125</xref>). RASGRP1-deficient T cells showed impaired ERK/MAPK activation and decreased T-cell proliferation in response to mitogens and antigens (<xref ref-type="bibr" rid="B119">119</xref>, <xref ref-type="bibr" rid="B120">120</xref>). In the first report, RASGRP1-deficient T cells were also shown to have diminished cell cytotoxicity and migration capacity (<xref ref-type="bibr" rid="B120">120</xref>). NK cells also exhibited decreased cell cytotoxicity. A direct role of RASGRP1 in cytoskeletal dynamics during exocytosis of lytic granules in NK and T cells and in T-cell migration is suggested by its ability to interact with the dynein light chain DYNLL1 and to activate RhoA, respectively (<xref ref-type="bibr" rid="B120">120</xref>). This role may explain the impaired cytotoxic responses seen in RASGRP1-deficient T and NK cells. In a recent report by Winter et al., RASGRP1-deficient NK cells and CD8<sup>+</sup> T cells were nonetheless found to have normal degranulation when stimulated (<xref ref-type="bibr" rid="B119">119</xref>). The discrepancy between these studies is not known. However, in the different reports, low numbers of NK cells were consistently noticed in RASGRP1-deficient patients that might contribute to the decreased NK cell cytotoxicity. Winter et al. further analyzed the possible mechanisms underlying the EBV susceptibility in RASGRP1 deficiency and showed that RASGRP1-deficient T cells failed to expand normally (<xref ref-type="bibr" rid="B119">119</xref>). In particular, RASGRP1-deficient T cells had impaired CD27-dependent proliferation toward CD70-expressing EBV-transformed B cells, a critical pathway to expand EBV-specific T cells (see above). Interestingly, the impaired proliferation of activated RASGRP1-deficient T cells correlated with their inability to upregulate CTPS1 protein expression, suggestive of a role of RASGRP1/MAPK pathway in CTPS1 expression, but also in other factors involved in T-cell proliferation, as CTP or cytidine failed to restore impaired proliferation of RASGRP1-deficient T cells (<xref ref-type="bibr" rid="B119">119</xref>).</p>
<p>Two <italic>RASGRP1</italic> heterozygous compound mutations with no effect on RASGRP1 protein expression have been also recently identified in two siblings with multiple fungal, bacterial, and viral infections including EBV and CMV, and both also developed autoimmunity signs evoking autoimmune lymphoproliferative syndrome (<xref ref-type="bibr" rid="B126">126</xref>). Along these lines, RASGRP1-deficient mice developed autoimmune LPD resembling systemic lupus erythematous when getting older (<xref ref-type="bibr" rid="B127">127</xref>, <xref ref-type="bibr" rid="B128">128</xref>) and RASGRP1 is considered as a risk locus for autoimmunity (<xref ref-type="bibr" rid="B129">129</xref>–<xref ref-type="bibr" rid="B131">131</xref>). T cells from the two patients showed defective TCR activation associated with impaired proliferation and AICD. However, complementation experiments with wild-type RASGRP1 were unsuccessful, leaving the possibility that other or additional genetic events contribute to this particular phenotype and/or these mutations do not behave as loss-of-function mutations. These observations could suggest a genotype–phenotype correlation.</p>
</sec>
<sec id="S10">
<title>Pathways in the Control of EBV Infection</title>
<p>Several key pathways required for an efficient immunity to EBV have emerged from studies of these genetic disorders (<xref ref-type="bibr" rid="B11">11</xref>). Interestingly, these pathways are involved in the cell–cell interaction and cross-talk between T and B cells and appear to play a critical role in the immune surveillance of B cells by T cells, which is consistent with B cells as the privileged target of EBV infection and the reservoir of EBV. These pathways implicate pairs of receptor–ligand expressed by T and B cells, respectively (Figure <xref ref-type="fig" rid="F1">1</xref>). The best known and in depth studied is the SLAMR–SAP pathway, which is defective in the SAP deficiency/XLP-1 syndrome and mainly involves two SLAM receptors, 2B4 and NTB-A; however, other SLAMR such as CD229 may be also implicated as suggested from mice and human studies (<xref ref-type="bibr" rid="B47">47</xref>, <xref ref-type="bibr" rid="B49">49</xref>). These pathways appear to be important in the recognition of EBV-infected B cells by T cells and in the activation of the T- and NK-cell cytotoxicity responses toward EBV-infected B cells. Another important pathway is dependent of the NKG2D receptor, well known to activate T- and NK-cell cytotoxic responses. In the absence of MAGT1, NKG2D expression on CD8<sup>+</sup> T cells and NK cells is impaired leading to defective killing of EBV-infected B cells (<xref ref-type="bibr" rid="B79">79</xref>). Nevertheless, it would be interesting to know whether EBV-specific T cells expand normally in MAGT1-deficient patients as NKG2D has been also involved in the survival and expansion of CD8<sup>+</sup> T cells during viral infections. The pair CD27–CD70 molecules forms a critical axis required for survival and expansion of EBV-specific T cells (<xref ref-type="bibr" rid="B91">91</xref>). The key role of T-cell expansion/proliferation to control EBV-infected B cells is also highlighted by the CTPS1 and RASGRP1 deficiencies, in which the capacity of T lymphocytes to proliferate in response to antigenic stimulation is specifically impaired.</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p>Schematic representation of defective identified pathways in immunodeficiencies predisposing to high susceptility to Epstein–Barr virus (EBV)-driven B-cell lymphoproliferative diseases. Defective components in the pathways are in yellow. Three non-redundant pathways have been shown to be impaired: the SLAMF6/2B4/SLAM-associated protein (SAP) pathway, the CD70/CD27 pathway, and the NKG2D/MICA/MAGT1 pathway. At some point, several of these pathways may converge toward distal effector molecules such as RASGRP1 and CTPS1 that are required for expansion of T cells. The connection of CORO1A to these pathways is not known. Besides the essential role of CD8<sup>+</sup> T cells, NK and iNKT cells which are often decreased in these primary imunodeficiencies may play a role in the immune response against EBV, particularly during the early phase of the primary infection. Vγ9δ2 T cells are also thought to play an important role in the primary infection by recognition of latently EBV-replicating B cells.</p>
</caption>
<graphic xlink:href="fimmu-09-01103-g001"></graphic>
</fig>
<p>Most of these deficiencies are characterized by a marked decreased or absence of invariant T cell populations iNKT and mucosal-associated invariant T (MAIT) cells, which raises the question of the role of these cells in immunity to EBV. iNKT cells are characterized by innate-like properties including prompt activation and production of large amounts of cytokines. These cells have been involved in a variety of immune responses including anti-viral immunity. Mice models have provided the evidence that SAP, ITK, and RASGRP1 are directly implicated in the development/homeostasis/function of iNKT cells (<xref ref-type="bibr" rid="B132">132</xref>–<xref ref-type="bibr" rid="B137">137</xref>). Analysis of XIAP-deficient patients also indicated that these cellular defects can be secondary to the EBV infection, leading to cell exhaustion in relation with the peculiar high sensitivity of iNKT and MAIT cells to AICD (<xref ref-type="bibr" rid="B138">138</xref>). There are only limited studies that assessed the role of iNKT cells in EBV infection, though it was shown that iNKT cells, in particular CD8<sup>+</sup> iNKT cells have the capacity to directly lyse EBV-infected B cells expressing CD1d and to limit expansion of EBV-transformed B cells both <italic>in vitro</italic> and <italic>in vivo</italic> (<xref ref-type="bibr" rid="B139">139</xref>–<xref ref-type="bibr" rid="B141">141</xref>). However, RORC-deficient patients, who lack iNKT and MAIT cells are not particularly susceptible to EBV, indicating that these cells are not playing a critical role in immunity to EBV (<xref ref-type="bibr" rid="B142">142</xref>). Altered functions and decreased counts of NK cells are also often observed in a number of these immunodeficiencies. The role of NK cells might be particularly important during childhood, since KIR-negative early differentiated NK cells that expanded preferentially during IM and targeted lytically EBV-replicating B cells, progressively disappeared in the first decade of life (<xref ref-type="bibr" rid="B143">143</xref>). Recent data indicated that patients with severe combined immunodeficiency (SCID) who received bone marrow transplanted, although devoided of NK cells after immune reconstitution display an efficient immunity to EBV since none of them developed EBV-driven lymphoproliferation disorders, even 39 years after the transplantation (<xref ref-type="bibr" rid="B144">144</xref>). This suggests that NK cells are not essential for EBV immunity throughout the life. In any event, although they are not key components, accumulation of these different cellular defects might participate to the susceptibility to EBV in these genetic settings, particularly during childhood. CD4 T cell lymphopenia that is observed in several of these disease may also participate to EBV susceptibility, although the role of CD4<sup>+</sup> T cells in the control of EBV infection is not clearly established (<xref ref-type="bibr" rid="B3">3</xref>). Arguing against a relevant role of CD4<sup>+</sup> T cells, patients with MHC class II deficiency have a severe CD4 lymphopenia and do not develop EBV-driven LPDs and they have normal B cell counts. Although not really considered, some of these defects could also have intrinsic B-cell consequences that would further favor proliferation and/or lymphomagenesis of EBV-infected B cells in addition to the immune deficiency. In that respect, CD70 was shown to elicit reverse signaling involved in apoptosis of B cells and the recent study of MAGT1-deficient mice revealed a regulatory role of MAGT1 in B-cell development and proliferation that may explain the B lymphocytosis found in MAGT1-deficient patients (<xref ref-type="bibr" rid="B86">86</xref>, <xref ref-type="bibr" rid="B145">145</xref>).</p>
</sec>
<sec id="S11">
<title>Differential Diagnosis</title>
<p>Given the importance of the CD8<sup>+</sup> T-cell response in immunity to EBV, it is not surprising that EBV-driven LPDs are also found in other PIDs associated with T-cell defects, but with a lower frequency. Herpes virus, in particular EBV, are often the trigger of HLH in patients with familial haemophagocytic lymphohistiocytosis (FHL), a group of diseases associated with impaired cytolytic activity of CD8<sup>+</sup> T cells and NK cells. These diseases are caused by gene defects in the perforin gene and in the components of lytic granule exocytosis machinery (<xref ref-type="bibr" rid="B146">146</xref>). Patients with CVID or CID, particularly those affecting T-cell survival, migration, and F-actin mobilization in T cells, can also develop EBV-associated disorders (<xref ref-type="bibr" rid="B12">12</xref>). Those include, among others, deficiencies in NFκB1 (<xref ref-type="bibr" rid="B147">147</xref>), MST1/STK4 (<xref ref-type="bibr" rid="B148">148</xref>, <xref ref-type="bibr" rid="B149">149</xref>), WASP (<xref ref-type="bibr" rid="B150">150</xref>), DOCK8 (<xref ref-type="bibr" rid="B151">151</xref>), GATA2 (<xref ref-type="bibr" rid="B152">152</xref>), and gain-of-function mutations in <italic>PIK3CD</italic> known to cause activated PI3K-delta syndrome (<xref ref-type="bibr" rid="B153">153</xref>). Patients with hypomorphic mutations in genes involved in T-cell development such as RAG1/2, DCLRE1C (ARTEMIS), or ZAP-70 can also experience EBV susceptibility (<xref ref-type="bibr" rid="B154">154</xref>–<xref ref-type="bibr" rid="B156">156</xref>). It should be considered that patients with the most severe T-cell defects will never present EBV problems since they develop very early-onset severe infections (other than EBV), requiring rapid bone marrow transplantation before they encounter EBV. At last, some of these immunodeficiencies (SCID) are also associated with a severe block in B-cell development, a cellular context that in all likelihood does not allow EBV infection establishment and dissemination.</p>
</sec>
<sec id="S12">
<title>Therapeutics</title>
<p>So far, the only curative treatment for these PIDs is hematopoietic stem cell transplantation (HSCT). The first studies on large cohorts of XLP-1 and XLP-2 patients reported poor survival with or without HSCT (<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B157">157</xref>). This pejorative prognosis was partly linked to the use of full conditioning regimens associated with a high toxicity in patients (XIAP) and/or the absence of HLH remission at the time of HSCT. In the last few years, the use of reduced intensity conditionings and the development of new therapies like alemtuzumab (anti-CD52 antibody) has strongly improved the management of these diseases (<xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B158">158</xref>, <xref ref-type="bibr" rid="B159">159</xref>). Furthermore, rituximab (anti-CD20 antibody) has now a major role in the management of LPDs associated with these PIDs with patients being in remission after having received this treatment.</p>
</sec>
<sec id="S13">
<title>Concluding Remarks</title>
<p>Molecular characterization of familial forms of EBV susceptibility has provided over the last 20 years, novel diagnostic tools for these disorders. Analysis of large cohorts and case reports have underlined non-EBV phenotypes associated with these PIDs such as IBD, pulmonary involvement, neurological disorders, or other typical infections (such as HPV), that can further help to the diagnosis. However, there are still a number of patients with a high susceptibility to EBV, in whom the molecular/genetic basis of their disease is not known and remains to be determined. In the light of the knowledge gained throughout the studies of the genetically determined forms of EBV susceptibility, we can speculate that these uncharacterized forms are caused by defects in molecules/components involved in T–B cell interactions and required for T-cell cytolytic responses and/or T-cell expansion.</p>
</sec>
<sec id="S14">
<title>Author Contributions</title>
<p>SL wrote the manuscript and made the Figure <xref ref-type="fig" rid="F1">1</xref>. SW compiled data for Tables <xref ref-type="table" rid="T1">1</xref> and <xref ref-type="table" rid="T2">2</xref> and did the tables and participated to the writing of the manuscript.</p>
</sec>
<sec id="S15">
<title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p><bold>Funding.</bold> SL is a senior scientist at the Centre National de la Recherche Scientifique-CNRS (France). SW is supported by Imagine Institut PhD program funded by the Fondation Bettencourt-Schueller. The work of the Laboratory of Lymphocyte Activation and Susceptibility to EBV headed by SL is supported by grants from Ligue Contre le Cancer-Equipe Labellisée (France), INSERM (France), the Agence Nationale de la Recherche, France (ANR-14-CE14-0028-01 (SL) and ANR-10-IAHU-01 (Imagine Institut)), the Rare Diseases Fondation (France), the Association François Aupetit (France), the Société Française de Lutte contre les Cancers et Leucémies de l’Enfant et de l’Adolescent (SFCE), AREMIG (France), Fédération Enfants et Santé (France), and the European Research Council (ERC-2009-AdG_20090506 no FP7-249816).</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>JI</given-names></name><name><surname>Fauci</surname><given-names>AS</given-names></name><name><surname>Varmus</surname><given-names>H</given-names></name><name><surname>Nabel</surname><given-names>GJ</given-names></name></person-group>
<article-title>Epstein-Barr virus: an important vaccine target for cancer prevention</article-title>. <source/>Sci Transl Med (<year>2011</year>) <volume>3</volume>:<fpage>107fs107</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3002878</pub-id></mixed-citation>
</ref>
<ref id="B2">
<label>2</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hislop</surname><given-names>AD</given-names></name><name><surname>Taylor</surname><given-names>GS</given-names></name><name><surname>Sauce</surname><given-names>D</given-names></name><name><surname>Rickinson</surname><given-names>AB</given-names></name></person-group>. <article-title>Cellular responses to viral infection in humans: lessons from Epstein-Barr virus</article-title>. <source/>Annu Rev Immunol (<year>2007</year>) <volume>25</volume>:<fpage>587</fpage>–<lpage>617</lpage>.<pub-id pub-id-type="doi">10.1146/annurev.immunol.25.022106.141553</pub-id><pub-id pub-id-type="pmid">17378764</pub-id></mixed-citation>
</ref>
<ref id="B3">
<label>3</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>GS</given-names></name><name><surname>Long</surname><given-names>HM</given-names></name><name><surname>Brooks</surname><given-names>JM</given-names></name><name><surname>Rickinson</surname><given-names>AB</given-names></name><name><surname>Hislop</surname><given-names>AD</given-names></name></person-group>. <article-title>The immunology of Epstein-Barr virus-induced disease</article-title>. <source/>Annu Rev Immunol (<year>2015</year>) <volume>33</volume>:<fpage>787</fpage>–<lpage>821</lpage>.<pub-id pub-id-type="doi">10.1146/annurev-immunol-032414-112326</pub-id><pub-id pub-id-type="pmid">25706097</pub-id></mixed-citation>
</ref>
<ref id="B4">
<label>4</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munz</surname><given-names>C</given-names></name></person-group>. <article-title>Epstein-Barr virus-specific immune control by innate lymphocytes</article-title>. <source/>Front Immunol (<year>2017</year>) <volume>8</volume>:<fpage>1658</fpage>.<pub-id pub-id-type="doi">10.3389/fimmu.2017.01658</pub-id><pub-id pub-id-type="pmid">29225606</pub-id></mixed-citation>
</ref>
<ref id="B5">
<label>5</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Djaoud</surname><given-names>Z</given-names></name><name><surname>Guethlein</surname><given-names>LA</given-names></name><name><surname>Horowitz</surname><given-names>A</given-names></name><name><surname>Azzi</surname><given-names>T</given-names></name><name><surname>Nemat-Gorgani</surname><given-names>N</given-names></name><name><surname>Olive</surname><given-names>D</given-names></name><etal></etal></person-group>
<article-title>Two alternate strategies for innate immunity to Epstein-Barr virus: one using NK cells and the other NK cells and gammadelta T cells</article-title>. <source/>J Exp Med (<year>2017</year>) <volume>214</volume>:<fpage>1827</fpage>–<lpage>41</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20161017</pub-id><pub-id pub-id-type="pmid">28468758</pub-id></mixed-citation>
</ref>
<ref id="B6">
<label>6</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujiwara</surname><given-names>S</given-names></name><name><surname>Kimura</surname><given-names>H</given-names></name><name><surname>Imadome</surname><given-names>K-I</given-names></name><name><surname>Arai</surname><given-names>A</given-names></name><name><surname>Kodama</surname><given-names>E</given-names></name><name><surname>Morio</surname><given-names>T</given-names></name><etal></etal></person-group>
<article-title>Current research on chronic active Epstein-Barr virus infection in Japan</article-title>. <source/>Pediatr Int (<year>2014</year>) <volume>56</volume>:<fpage>159</fpage>–<lpage>66</lpage>.<pub-id pub-id-type="doi">10.1111/ped.12314</pub-id><pub-id pub-id-type="pmid">24528553</pub-id></mixed-citation>
</ref>
<ref id="B7">
<label>7</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname><given-names>H</given-names></name><name><surname>Cohen</surname><given-names>JI</given-names></name></person-group>. <article-title>Chronic active Epstein-Barr virus disease</article-title>. <source/>Front Immunol (<year>2017</year>) <volume>8</volume>:<fpage>1867</fpage>.<pub-id pub-id-type="doi">10.3389/fimmu.2017.01867</pub-id><pub-id pub-id-type="pmid">29375552</pub-id></mixed-citation>
</ref>
<ref id="B8">
<label>8</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Callan</surname><given-names>MF</given-names></name><name><surname>Tan</surname><given-names>L</given-names></name><name><surname>Annels</surname><given-names>N</given-names></name><name><surname>Ogg</surname><given-names>GS</given-names></name><name><surname>Wilson</surname><given-names>JD</given-names></name><name><surname>O’Callaghan</surname><given-names>CA</given-names></name><etal></etal></person-group>
<article-title>Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo</article-title>. <source/>J Exp Med (<year>1998</year>) <volume>187</volume>:<fpage>1395</fpage>–<lpage>402</lpage>.<pub-id pub-id-type="doi">10.1084/jem.187.9.1395</pub-id><pub-id pub-id-type="pmid">9565632</pub-id></mixed-citation>
</ref>
<ref id="B9">
<label>9</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bibas</surname><given-names>M</given-names></name><name><surname>Antinori</surname><given-names>A</given-names></name></person-group>. <article-title>EBV and HIV-related lymphoma</article-title>. <source/>Mediterr J Hematol Infect Dis (<year>2009</year>) <volume>1</volume>:<fpage>e2009032</fpage>.<pub-id pub-id-type="doi">10.4084/MJHID.2009.032</pub-id><pub-id pub-id-type="pmid">21416008</pub-id></mixed-citation>
</ref>
<ref id="B10">
<label>10</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veillette</surname><given-names>A</given-names></name><name><surname>Perez-Quintero</surname><given-names>LA</given-names></name><name><surname>Latour</surname><given-names>S</given-names></name></person-group>. <article-title>X-linked lymphoproliferative syndromes and related autosomal recessive disorders</article-title>. <source/>Curr Opin Allergy Clin Immunol (<year>2013</year>) <volume>13</volume>:<fpage>614</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="doi">10.1097/ACI.0000000000000008</pub-id><pub-id pub-id-type="pmid">24113228</pub-id></mixed-citation>
</ref>
<ref id="B11">
<label>11</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tangye</surname><given-names>SG</given-names></name><name><surname>Palendira</surname><given-names>U</given-names></name><name><surname>Edwards</surname><given-names>ES</given-names></name></person-group>. <article-title>Human immunity against EBV-lessons from the clinic</article-title>. <source/>J Exp Med (<year>2017</year>) <volume>214</volume>:<fpage>269</fpage>–<lpage>83</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20161846</pub-id><pub-id pub-id-type="pmid">28108590</pub-id></mixed-citation>
</ref>
<ref id="B12">
<label>12</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>JI</given-names></name></person-group>. <article-title>Primary immunodeficiencies associated with EBV disease</article-title>. <source/>Curr Top Microbiol Immunol (<year>2015</year>) <volume>390</volume>:<fpage>241</fpage>–<lpage>65</lpage>.<pub-id pub-id-type="doi">10.1007/978-3-319-22822-8_10</pub-id><pub-id pub-id-type="pmid">26424649</pub-id></mixed-citation>
</ref>
<ref id="B13">
<label>13</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>A</given-names></name></person-group>. <article-title>Recent advances in understanding the pathophysiology of primary T cell immunodeficiencies</article-title>. <source/>Trends Mol Med (<year>2015</year>) <volume>21</volume>:<fpage>408</fpage>–<lpage>16</lpage>.<pub-id pub-id-type="doi">10.1016/j.molmed.2015.04.002</pub-id><pub-id pub-id-type="pmid">25953674</pub-id></mixed-citation>
</ref>
<ref id="B14">
<label>14</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Notarangelo</surname><given-names>LD</given-names></name></person-group>. <article-title>Combined immunodeficiencies with nonfunctional T lymphocytes</article-title>. <source/>Adv Immunol (<year>2014</year>) <volume>121</volume>:<fpage>121</fpage>–<lpage>90</lpage>.<pub-id pub-id-type="doi">10.1016/B978-0-12-800100-4.00004-0</pub-id><pub-id pub-id-type="pmid">24388215</pub-id></mixed-citation>
</ref>
<ref id="B15">
<label>15</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sayos</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Morra</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Allen</surname><given-names>D</given-names></name><etal></etal></person-group>
<article-title>The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM</article-title>. <source/>Nature (<year>1998</year>) <volume>395</volume>:<fpage>462</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1038/26683</pub-id><pub-id pub-id-type="pmid">9774102</pub-id></mixed-citation>
</ref>
<ref id="B16">
<label>16</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coffey</surname><given-names>AJ</given-names></name><name><surname>Brooksbank</surname><given-names>RA</given-names></name><name><surname>Brandau</surname><given-names>O</given-names></name><name><surname>Oohashi</surname><given-names>T</given-names></name><name><surname>Howell</surname><given-names>GR</given-names></name><name><surname>Bye</surname><given-names>JM</given-names></name><etal></etal></person-group>
<article-title>Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene</article-title>. <source/>Nat Genet (<year>1998</year>) <volume>20</volume>:<fpage>129</fpage>–<lpage>35</lpage>.<pub-id pub-id-type="doi">10.1038/2424</pub-id><pub-id pub-id-type="pmid">9771704</pub-id></mixed-citation>
</ref>
<ref id="B17">
<label>17</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nichols</surname><given-names>KE</given-names></name><name><surname>Harkin</surname><given-names>DP</given-names></name><name><surname>Levitz</surname><given-names>S</given-names></name><name><surname>Krainer</surname><given-names>M</given-names></name><name><surname>Kolquist</surname><given-names>KA</given-names></name><name><surname>Genovese</surname><given-names>C</given-names></name><etal></etal></person-group>
<article-title>Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome</article-title>. <source/>Proc Natl Acad Sci U S A (<year>1998</year>) <volume>95</volume>:<fpage>13765</fpage>–<lpage>70</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.95.23.13765</pub-id><pub-id pub-id-type="pmid">9811875</pub-id></mixed-citation>
</ref>
<ref id="B18">
<label>18</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tangye</surname><given-names>SG</given-names></name></person-group>. <article-title>XLP: clinical features and molecular etiology due to mutations in SH2D1A encoding SAP</article-title>. <source/>J Clin Immunol (<year>2014</year>) <volume>34</volume>:<fpage>772</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1007/s10875-014-0083-7</pub-id><pub-id pub-id-type="pmid">25085526</pub-id></mixed-citation>
</ref>
<ref id="B19">
<label>19</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaspar</surname><given-names>HB</given-names></name><name><surname>Sharifi</surname><given-names>R</given-names></name><name><surname>Gilmour</surname><given-names>KC</given-names></name><name><surname>Thrasher</surname><given-names>AJ</given-names></name></person-group>
<article-title>X-linked lymphoproliferative disease: clinical, diagnostic and molecular perspective</article-title>. <source/>Br J Haematol (<year>2002</year>) <volume>119</volume>:<fpage>585</fpage>–<lpage>95</lpage>.<pub-id pub-id-type="doi">10.1046/j.1365-2141.2002.03851.x</pub-id><pub-id pub-id-type="pmid">12437631</pub-id></mixed-citation>
</ref>
<ref id="B20">
<label>20</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purtilo</surname><given-names>DT</given-names></name><name><surname>Sakamoto</surname><given-names>K</given-names></name><name><surname>Barnabei</surname><given-names>V</given-names></name><name><surname>Seeley</surname><given-names>J</given-names></name><name><surname>Bechtold</surname><given-names>T</given-names></name><name><surname>Rogers</surname><given-names>G</given-names></name><etal></etal></person-group>
<article-title>Epstein-Barr virus-induced diseases in boys with the X-linked lymphoproliferative syndrome (XLP): update on studies of the registry</article-title>. <source/>Am J Med (<year>1982</year>) <volume>73</volume>:<fpage>49</fpage>–<lpage>56</lpage>.<pub-id pub-id-type="doi">10.1016/0002-9343(82)90923-8</pub-id><pub-id pub-id-type="pmid">6283885</pub-id></mixed-citation>
</ref>
<ref id="B21">
<label>21</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sumegi</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name><name><surname>Lanyi</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>JD</given-names></name><name><surname>Seemayer</surname><given-names>TA</given-names></name><name><surname>Maeda</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Correlation of mutations of the SH2D1A gene and Epstein-Barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease</article-title>. <source/>Blood (<year>2000</year>) <volume>96</volume>:<fpage>3118</fpage>–<lpage>25</lpage>.<pub-id pub-id-type="pmid">11049992</pub-id></mixed-citation>
</ref>
<ref id="B22">
<label>22</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanegane</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Yamato</surname><given-names>K</given-names></name><name><surname>Inoue</surname><given-names>M</given-names></name><name><surname>Hamamoto</surname><given-names>K</given-names></name><etal></etal></person-group>
<article-title>Clinical features and outcome of X-linked lymphoproliferative syndrome type 1 (SAP deficiency) in Japan identified by the combination of flow cytometric assay and genetic analysis</article-title>. <source/>Pediatr Allergy Immunol (<year>2012</year>) <volume>23</volume>:<fpage>488</fpage>–<lpage>93</lpage>.<pub-id pub-id-type="doi">10.1111/j.1399-3038.2012.01282.x</pub-id><pub-id pub-id-type="pmid">22433061</pub-id></mixed-citation>
</ref>
<ref id="B23">
<label>23</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Booth</surname><given-names>C</given-names></name><name><surname>Gilmour</surname><given-names>KC</given-names></name><name><surname>Veys</surname><given-names>P</given-names></name><name><surname>Gennery</surname><given-names>AR</given-names></name><name><surname>Slatter</surname><given-names>MA</given-names></name><name><surname>Chapel</surname><given-names>H</given-names></name><etal></etal></person-group>
<article-title>X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease</article-title>. <source/>Blood (<year>2011</year>) <volume>117</volume>:<fpage>53</fpage>–<lpage>62</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2010-06-284935</pub-id><pub-id pub-id-type="pmid">20926771</pub-id></mixed-citation>
</ref>
<ref id="B24">
<label>24</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pachlopnik Schmid</surname><given-names>J</given-names></name><name><surname>Canioni</surname><given-names>D</given-names></name><name><surname>Moshous</surname><given-names>D</given-names></name><name><surname>Touzot</surname><given-names>F</given-names></name><name><surname>Mahlaoui</surname><given-names>N</given-names></name><name><surname>Hauck</surname><given-names>F</given-names></name><etal></etal></person-group>
<article-title>Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency)</article-title>. <source/>Blood (<year>2011</year>) <volume>117</volume>:<fpage>1522</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2010-07-298372</pub-id><pub-id pub-id-type="pmid">21119115</pub-id></mixed-citation>
</ref>
<ref id="B25">
<label>25</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talaat</surname><given-names>KR</given-names></name><name><surname>Rothman</surname><given-names>JA</given-names></name><name><surname>Cohen</surname><given-names>JI</given-names></name><name><surname>Santi</surname><given-names>M</given-names></name><name><surname>Choi</surname><given-names>JK</given-names></name><name><surname>Guzman</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Lymphocytic vasculitis involving the central nervous system occurs in patients with X-linked lymphoproliferative disease in the absence of Epstein-Barr virus infection</article-title>. <source/>Pediatr Blood Cancer (<year>2009</year>) <volume>53</volume>:<fpage>1120</fpage>–<lpage>3</lpage>.<pub-id pub-id-type="doi">10.1002/pbc.22185</pub-id><pub-id pub-id-type="pmid">19621458</pub-id></mixed-citation>
</ref>
<ref id="B26">
<label>26</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>PE</given-names></name><name><surname>O’Brien</surname><given-names>TA</given-names></name><name><surname>Wagle</surname><given-names>M</given-names></name><name><surname>Tangye</surname><given-names>SG</given-names></name><name><surname>Palendira</surname><given-names>U</given-names></name><name><surname>Roscioli</surname><given-names>T</given-names></name><etal></etal></person-group>
<article-title>Cerebral vasculitis in X-linked lymphoproliferative disease cured by matched unrelated cord blood transplant</article-title>. <source/>J Clin Immunol (<year>2015</year>) <volume>35</volume>:<fpage>604</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1007/s10875-015-0194-9</pub-id><pub-id pub-id-type="pmid">26433589</pub-id></mixed-citation>
</ref>
<ref id="B27">
<label>27</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seemayer</surname><given-names>TA</given-names></name><name><surname>Gross</surname><given-names>TG</given-names></name><name><surname>Egeler</surname><given-names>RM</given-names></name><name><surname>Pirruccello</surname><given-names>SJ</given-names></name><name><surname>Davis</surname><given-names>JR</given-names></name><name><surname>Kelly</surname><given-names>CM</given-names></name><etal></etal></person-group>
<article-title>X-linked lymphoproliferative disease: twenty-five years after the discovery</article-title>. <source/>Pediatr Res (<year>1995</year>) <volume>38</volume>:<fpage>471</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1203/00006450-199510000-00001</pub-id><pub-id pub-id-type="pmid">8559596</pub-id></mixed-citation>
</ref>
<ref id="B28">
<label>28</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morra</surname><given-names>M</given-names></name><name><surname>Silander</surname><given-names>O</given-names></name><name><surname>Calpe</surname><given-names>S</given-names></name><name><surname>Choi</surname><given-names>M</given-names></name><name><surname>Oettgen</surname><given-names>H</given-names></name><name><surname>Myers</surname><given-names>L</given-names></name><etal></etal></person-group>
<article-title>Alterations of the X-linked lymphoproliferative disease gene SH2D1A in common variable immunodeficiency syndrome</article-title>. <source/>Blood (<year>2001</year>) <volume>98</volume>:<fpage>1321</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1182/blood.V98.5.1321</pub-id><pub-id pub-id-type="pmid">11520777</pub-id></mixed-citation>
</ref>
<ref id="B29">
<label>29</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eastwood</surname><given-names>D</given-names></name><name><surname>Gilmour</surname><given-names>KC</given-names></name><name><surname>Nistala</surname><given-names>K</given-names></name><name><surname>Meaney</surname><given-names>C</given-names></name><name><surname>Chapel</surname><given-names>H</given-names></name><name><surname>Sherrell</surname><given-names>Z</given-names></name><etal></etal></person-group>
<article-title>Prevalence of SAP gene defects in male patients diagnosed with common variable immunodeficiency</article-title>. <source/>Clin Exp Immunol (<year>2004</year>) <volume>137</volume>:<fpage>584</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1111/j.1365-2249.2004.02581.x</pub-id><pub-id pub-id-type="pmid">15320910</pub-id></mixed-citation>
</ref>
<ref id="B30">
<label>30</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nistala</surname><given-names>K</given-names></name><name><surname>Gilmour</surname><given-names>KC</given-names></name><name><surname>Cranston</surname><given-names>T</given-names></name><name><surname>Davies</surname><given-names>EG</given-names></name><name><surname>Goldblatt</surname><given-names>D</given-names></name><name><surname>Gaspar</surname><given-names>HB</given-names></name><etal></etal></person-group>
<article-title>X-linked lymphoproliferative disease: three atypical cases</article-title>. <source/>Clin Exp Immunol (<year>2001</year>) <volume>126</volume>:<fpage>126</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="doi">10.1046/j.1365-2249.2001.01599.x</pub-id><pub-id pub-id-type="pmid">11678908</pub-id></mixed-citation>
</ref>
<ref id="B31">
<label>31</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soresina</surname><given-names>A</given-names></name><name><surname>Lougaris</surname><given-names>V</given-names></name><name><surname>Giliani</surname><given-names>S</given-names></name><name><surname>Cardinale</surname><given-names>F</given-names></name><name><surname>Armenio</surname><given-names>L</given-names></name><name><surname>Cattalini</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Mutations of the X-linked lymphoproliferative disease gene SH2D1A mimicking common variable immunodeficiency</article-title>. <source/>Eur J Pediatr (<year>2002</year>) <volume>161</volume>:<fpage>656</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1007/s00431-002-1083-9</pub-id><pub-id pub-id-type="pmid">12447665</pub-id></mixed-citation>
</ref>
<ref id="B32">
<label>32</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Tian</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Teng</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Tong</surname><given-names>C</given-names></name><etal></etal></person-group>
<article-title>Maternal onset de novo SH2D1A mutation and lymphocytic choriomeningitis virus infection in a patient with X-linked lymphoproliferative disease type 1: a case report</article-title>. <source/>Mol Med Rep (<year>2015</year>) <volume>11</volume>:<fpage>3291</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="doi">10.3892/mmr.2015.3173</pub-id><pub-id pub-id-type="pmid">25572984</pub-id></mixed-citation>
</ref>
<ref id="B33">
<label>33</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marsh</surname><given-names>RA</given-names></name><name><surname>Bleesing</surname><given-names>JJ</given-names></name><name><surname>Chandrakasan</surname><given-names>S</given-names></name><name><surname>Jordan</surname><given-names>MB</given-names></name><name><surname>Davies</surname><given-names>SM</given-names></name><name><surname>Filipovich</surname><given-names>AH</given-names></name></person-group>. <article-title>Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated protein deficiency/X-linked lymphoproliferative disease type 1</article-title>. <source/>Biol Blood Marrow Transplant (<year>2014</year>) <volume>20</volume>:<fpage>1641</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1016/j.bbmt.2014.06.003</pub-id><pub-id pub-id-type="pmid">24923536</pub-id></mixed-citation>
</ref>
<ref id="B34">
<label>34</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veillette</surname><given-names>A</given-names></name></person-group>. <article-title>Immune regulation by SLAM family receptors and SAP-related adaptors</article-title>. <source/>Nat Rev Immunol (<year>2006</year>) <volume>6</volume>:<fpage>56</fpage>–<lpage>66</lpage>.<pub-id pub-id-type="doi">10.1038/nri1761</pub-id><pub-id pub-id-type="pmid">16493427</pub-id></mixed-citation>
</ref>
<ref id="B35">
<label>35</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veillette</surname><given-names>A</given-names></name><name><surname>Dong</surname><given-names>Z</given-names></name><name><surname>Perez-Quintero</surname><given-names>LA</given-names></name><name><surname>Zhong</surname><given-names>MC</given-names></name><name><surname>Cruz-Munoz</surname><given-names>ME</given-names></name></person-group>. <article-title>Importance and mechanism of ’switch’ function of SAP family adapters</article-title>. <source/>Immunol Rev (<year>2009</year>) <volume>232</volume>:<fpage>229</fpage>–<lpage>39</lpage>.<pub-id pub-id-type="doi">10.1111/j.1600-065X.2009.00824.x</pub-id><pub-id pub-id-type="pmid">19909367</pub-id></mixed-citation>
</ref>
<ref id="B36">
<label>36</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cannons</surname><given-names>JL</given-names></name><name><surname>Tangye</surname><given-names>SG</given-names></name><name><surname>Schwartzberg</surname><given-names>PL</given-names></name></person-group>. <article-title>SLAM family receptors and SAP adaptors in immunity</article-title>. <source/>Annu Rev Immunol (<year>2011</year>) <volume>29</volume>:<fpage>665</fpage>–<lpage>705</lpage>.<pub-id pub-id-type="doi">10.1146/annurev-immunol-030409-101302</pub-id><pub-id pub-id-type="pmid">21219180</pub-id></mixed-citation>
</ref>
<ref id="B37">
<label>37</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Latour</surname><given-names>S</given-names></name><name><surname>Roncagalli</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Bakinowski</surname><given-names>M</given-names></name><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Schwartzberg</surname><given-names>PL</given-names></name><etal></etal></person-group>
<article-title>Binding of SAP SH2 domain to FynT SH3 domain reveals a novel mechanism of receptor signalling in immune regulation</article-title>. <source/>Nat Cell Biol (<year>2003</year>) <volume>5</volume>:<fpage>149</fpage>–<lpage>54</lpage>.<pub-id pub-id-type="doi">10.1038/ncb919</pub-id><pub-id pub-id-type="pmid">12545173</pub-id></mixed-citation>
</ref>
<ref id="B38">
<label>38</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Latour</surname><given-names>S</given-names></name><name><surname>Gish</surname><given-names>G</given-names></name><name><surname>Helgason</surname><given-names>CD</given-names></name><name><surname>Humphries</surname><given-names>RK</given-names></name><name><surname>Pawson</surname><given-names>T</given-names></name><name><surname>Veillette</surname><given-names>A</given-names></name></person-group>. <article-title>Regulation of SLAM-mediated signal transduction by SAP, the X-linked lymphoproliferative gene product</article-title>. <source/>Nat Immunol (<year>2001</year>) <volume>2</volume>:<fpage>681</fpage>–<lpage>90</lpage>.<pub-id pub-id-type="doi">10.1038/90615</pub-id><pub-id pub-id-type="pmid">11477403</pub-id></mixed-citation>
</ref>
<ref id="B39">
<label>39</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>B</given-names></name><name><surname>Lanyi</surname><given-names>A</given-names></name><name><surname>Song</surname><given-names>HK</given-names></name><name><surname>Griesbach</surname><given-names>J</given-names></name><name><surname>Simarro-Grande</surname><given-names>M</given-names></name><name><surname>Poy</surname><given-names>F</given-names></name><etal></etal></person-group>
<article-title>SAP couples Fyn to SLAM immune receptors</article-title>. <source/>Nat Cell Biol (<year>2003</year>) <volume>5</volume>:<fpage>155</fpage>–<lpage>60</lpage>.<pub-id pub-id-type="doi">10.1038/ncb920</pub-id><pub-id pub-id-type="pmid">12545174</pub-id></mixed-citation>
</ref>
<ref id="B40">
<label>40</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harada</surname><given-names>S</given-names></name><name><surname>Bechtold</surname><given-names>T</given-names></name><name><surname>Seeley</surname><given-names>JK</given-names></name><name><surname>Purtilo</surname><given-names>DT</given-names></name></person-group>. <article-title>Cell-mediated immunity to Epstein-Barr virus (EBV) and natural killer (NK)-cell activity in the X-linked lymphoproliferative syndrome</article-title>. <source/>Int J Cancer (<year>1982</year>) <volume>30</volume>:<fpage>739</fpage>–<lpage>44</lpage>.<pub-id pub-id-type="doi">10.1002/ijc.2910300610</pub-id><pub-id pub-id-type="pmid">6298119</pub-id></mixed-citation>
</ref>
<ref id="B41">
<label>41</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harada</surname><given-names>S</given-names></name><name><surname>Sakamoto</surname><given-names>K</given-names></name><name><surname>Seeley</surname><given-names>JK</given-names></name><name><surname>Lindsten</surname><given-names>T</given-names></name><name><surname>Bechtold</surname><given-names>T</given-names></name><name><surname>Yetz</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Immune deficiency in the X-linked lymphoproliferative syndrome. I. Epstein-Barr virus-specific defects</article-title>. <source/>J Immunol (<year>1982</year>) <volume>129</volume>:<fpage>2532</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">6292290</pub-id></mixed-citation>
</ref>
<ref id="B42">
<label>42</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tangye</surname><given-names>SG</given-names></name><name><surname>Phillips</surname><given-names>JH</given-names></name><name><surname>Lanier</surname><given-names>LL</given-names></name><name><surname>Nichols</surname><given-names>KE</given-names></name></person-group>. <article-title>Functional requirement for SAP in 2B4-mediated activation of human natural killer cells as revealed by the X-linked lymphoproliferative syndrome</article-title>. <source/>J Immunol (<year>2000</year>) <volume>165</volume>:<fpage>2932</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.165.6.2932</pub-id><pub-id pub-id-type="pmid">10975798</pub-id></mixed-citation>
</ref>
<ref id="B43">
<label>43</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parolini</surname><given-names>S</given-names></name><name><surname>Bottino</surname><given-names>C</given-names></name><name><surname>Falco</surname><given-names>M</given-names></name><name><surname>Augugliaro</surname><given-names>R</given-names></name><name><surname>Giliani</surname><given-names>S</given-names></name><name><surname>Franceschini</surname><given-names>R</given-names></name><etal></etal></person-group>
<article-title>X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells</article-title>. <source/>J Exp Med (<year>2000</year>) <volume>192</volume>:<fpage>337</fpage>–<lpage>46</lpage>.<pub-id pub-id-type="doi">10.1084/jem.192.3.337</pub-id><pub-id pub-id-type="pmid">10934222</pub-id></mixed-citation>
</ref>
<ref id="B44">
<label>44</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bottino</surname><given-names>C</given-names></name><name><surname>Falco</surname><given-names>M</given-names></name><name><surname>Parolini</surname><given-names>S</given-names></name><name><surname>Marcenaro</surname><given-names>E</given-names></name><name><surname>Augugliaro</surname><given-names>R</given-names></name><name><surname>Sivori</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>NTB-A [correction of GNTB-A], a novel SH2D1A-associated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr virus-infected B cells in X-linked lymphoproliferative disease</article-title>. <source/>J Exp Med (<year>2001</year>) <volume>194</volume>:<fpage>235</fpage>–<lpage>46</lpage>.<pub-id pub-id-type="doi">10.1084/jem.194.3.235</pub-id><pub-id pub-id-type="pmid">11489943</pub-id></mixed-citation>
</ref>
<ref id="B45">
<label>45</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dupre</surname><given-names>L</given-names></name><name><surname>Andolfi</surname><given-names>G</given-names></name><name><surname>Tangye</surname><given-names>SG</given-names></name><name><surname>Clementi</surname><given-names>R</given-names></name><name><surname>Locatelli</surname><given-names>F</given-names></name><name><surname>Arico</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>SAP controls the cytolytic activity of CD8+ T cells against EBV-infected cells</article-title>. <source/>Blood (<year>2005</year>) <volume>105</volume>:<fpage>4383</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2004-08-3269</pub-id><pub-id pub-id-type="pmid">15677558</pub-id></mixed-citation>
</ref>
<ref id="B46">
<label>46</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharifi</surname><given-names>R</given-names></name><name><surname>Sinclair</surname><given-names>JC</given-names></name><name><surname>Gilmour</surname><given-names>KC</given-names></name><name><surname>Arkwright</surname><given-names>PD</given-names></name><name><surname>Kinnon</surname><given-names>C</given-names></name><name><surname>Thrasher</surname><given-names>AJ</given-names></name><etal></etal></person-group>
<article-title>SAP mediates specific cytotoxic T-cell functions in X-linked lymphoproliferative disease</article-title>. <source/>Blood (<year>2004</year>) <volume>103</volume>:<fpage>3821</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2003-09-3359</pub-id><pub-id pub-id-type="pmid">14726378</pub-id></mixed-citation>
</ref>
<ref id="B47">
<label>47</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hislop</surname><given-names>AD</given-names></name><name><surname>Palendira</surname><given-names>U</given-names></name><name><surname>Leese</surname><given-names>AM</given-names></name><name><surname>Arkwright</surname><given-names>PD</given-names></name><name><surname>Rohrlich</surname><given-names>PS</given-names></name><name><surname>Tangye</surname><given-names>SG</given-names></name><etal></etal></person-group>
<article-title>Impaired Epstein-Barr virus-specific CD8+ T-cell function in X-linked lymphoproliferative disease is restricted to SLAM family-positive B-cell targets</article-title>. <source/>Blood (<year>2010</year>) <volume>116</volume>:<fpage>3249</fpage>–<lpage>57</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2009-09-238832</pub-id><pub-id pub-id-type="pmid">20644117</pub-id></mixed-citation>
</ref>
<ref id="B48">
<label>48</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bloch-Queyrat</surname><given-names>C</given-names></name><name><surname>Fondaneche</surname><given-names>MC</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Yin</surname><given-names>L</given-names></name><name><surname>Relouzat</surname><given-names>F</given-names></name><name><surname>Veillette</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Regulation of natural cytotoxicity by the adaptor SAP and the Src-related kinase Fyn</article-title>. <source/>J Exp Med (<year>2005</year>) <volume>202</volume>:<fpage>181</fpage>–<lpage>92</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20050449</pub-id><pub-id pub-id-type="pmid">15998796</pub-id></mixed-citation>
</ref>
<ref id="B49">
<label>49</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>Z</given-names></name><name><surname>Cruz-Munoz</surname><given-names>ME</given-names></name><name><surname>Zhong</surname><given-names>MC</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Latour</surname><given-names>S</given-names></name><name><surname>Veillette</surname><given-names>A</given-names></name></person-group>. <article-title>Essential function for SAP family adaptors in the surveillance of hematopoietic cells by natural killer cells</article-title>. <source/>Nat Immunol (<year>2009</year>) <volume>10</volume>:<fpage>973</fpage>–<lpage>80</lpage>.<pub-id pub-id-type="doi">10.1038/ni.1763</pub-id><pub-id pub-id-type="pmid">19648922</pub-id></mixed-citation>
</ref>
<ref id="B50">
<label>50</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>Z</given-names></name><name><surname>Davidson</surname><given-names>D</given-names></name><name><surname>Perez-Quintero</surname><given-names>LA</given-names></name><name><surname>Kurosaki</surname><given-names>T</given-names></name><name><surname>Swat</surname><given-names>W</given-names></name><name><surname>Veillette</surname><given-names>A</given-names></name></person-group>. <article-title>The adaptor SAP controls NK cell activation by regulating the enzymes Vav-1 and SHIP-1 and by enhancing conjugates with target cells</article-title>. <source/>Immunity (<year>2012</year>) <volume>36</volume>:<fpage>974</fpage>–<lpage>85</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2012.03.023</pub-id><pub-id pub-id-type="pmid">22683124</pub-id></mixed-citation>
</ref>
<ref id="B51">
<label>51</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>F</given-names></name><name><surname>Cannons</surname><given-names>JL</given-names></name><name><surname>Dutta</surname><given-names>M</given-names></name><name><surname>Griffiths</surname><given-names>GM</given-names></name><name><surname>Schwartzberg</surname><given-names>PL</given-names></name></person-group>. <article-title>Positive and negative signaling through SLAM receptors regulate synapse organization and thresholds of cytolysis</article-title>. <source/>Immunity (<year>2012</year>) <volume>36</volume>:<fpage>1003</fpage>–<lpage>16</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2012.05.017</pub-id><pub-id pub-id-type="pmid">22683123</pub-id></mixed-citation>
</ref>
<ref id="B52">
<label>52</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>N</given-names></name><name><surname>Zhong</surname><given-names>MC</given-names></name><name><surname>Roncagalli</surname><given-names>R</given-names></name><name><surname>Perez-Quintero</surname><given-names>LA</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><etal></etal></person-group>
<article-title>A hematopoietic cell-driven mechanism involving SLAMF6 receptor, SAP adaptors and SHP-1 phosphatase regulates NK cell education</article-title>. <source/>Nat Immunol (<year>2016</year>) <volume>17</volume>:<fpage>387</fpage>–<lpage>96</lpage>.<pub-id pub-id-type="doi">10.1038/ni.3369</pub-id><pub-id pub-id-type="pmid">26878112</pub-id></mixed-citation>
</ref>
<ref id="B53">
<label>53</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palendira</surname><given-names>U</given-names></name><name><surname>Low</surname><given-names>C</given-names></name><name><surname>Chan</surname><given-names>A</given-names></name><name><surname>Hislop</surname><given-names>AD</given-names></name><name><surname>Ho</surname><given-names>E</given-names></name><name><surname>Phan</surname><given-names>TG</given-names></name><etal></etal></person-group>
<article-title>Molecular pathogenesis of EBV susceptibility in XLP as revealed by analysis of female carriers with heterozygous expression of SAP</article-title>. <source/>PLoS Biol (<year>2011</year>) <volume>9</volume>:<fpage>e1001187</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pbio.1001187</pub-id><pub-id pub-id-type="pmid">22069374</pub-id></mixed-citation>
</ref>
<ref id="B54">
<label>54</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rigaud</surname><given-names>S</given-names></name><name><surname>Fondaneche</surname><given-names>MC</given-names></name><name><surname>Lambert</surname><given-names>N</given-names></name><name><surname>Pasquier</surname><given-names>B</given-names></name><name><surname>Mateo</surname><given-names>V</given-names></name><name><surname>Soulas</surname><given-names>P</given-names></name><etal></etal></person-group>
<article-title>XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome</article-title>. <source/>Nature (<year>2006</year>) <volume>444</volume>:<fpage>110</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1038/nature05257</pub-id><pub-id pub-id-type="pmid">17080092</pub-id></mixed-citation>
</ref>
<ref id="B55">
<label>55</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snow</surname><given-names>AL</given-names></name><name><surname>Marsh</surname><given-names>RA</given-names></name><name><surname>Krummey</surname><given-names>SM</given-names></name><name><surname>Roehrs</surname><given-names>P</given-names></name><name><surname>Young</surname><given-names>LR</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><etal></etal></person-group>
<article-title>Restimulation-induced apoptosis of T cells is impaired in patients with X-linked lymphoproliferative disease caused by SAP deficiency</article-title>. <source/>J Clin Invest (<year>2009</year>) <volume>119</volume>:<fpage>2976</fpage>–<lpage>89</lpage>.<pub-id pub-id-type="doi">10.1172/JCI39518</pub-id><pub-id pub-id-type="pmid">19759517</pub-id></mixed-citation>
</ref>
<ref id="B56">
<label>56</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Tai</surname><given-names>AK</given-names></name><name><surname>Lin</surname><given-names>M</given-names></name><name><surname>Chang</surname><given-names>F</given-names></name><name><surname>Terhorst</surname><given-names>C</given-names></name><name><surname>Huber</surname><given-names>BT</given-names></name></person-group>. <article-title>Increased proliferation of CD8+ T cells in SAP-deficient mice is associated with impaired activation-induced cell death</article-title>. <source/>Eur J Immunol (<year>2007</year>) <volume>37</volume>:<fpage>663</fpage>–<lpage>74</lpage>.<pub-id pub-id-type="doi">10.1002/eji.200636417</pub-id><pub-id pub-id-type="pmid">17266174</pub-id></mixed-citation>
</ref>
<ref id="B57">
<label>57</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguilar</surname><given-names>C</given-names></name><name><surname>Latour</surname><given-names>S</given-names></name></person-group>. <article-title>X-linked inhibitor of apoptosis protein deficiency: more than an X-linked lymphoproliferative syndrome</article-title>. <source/>J Clin Immunol (<year>2015</year>) <volume>35</volume>:<fpage>331</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1007/s10875-015-0141-9</pub-id><pub-id pub-id-type="pmid">25737324</pub-id></mixed-citation>
</ref>
<ref id="B58">
<label>58</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Latour</surname><given-names>S</given-names></name><name><surname>Aguilar</surname><given-names>C</given-names></name></person-group>. <article-title>XIAP deficiency syndrome in humans</article-title>. <source/>Semin Cell Dev Biol (<year>2015</year>) <volume>39</volume>:<fpage>115</fpage>–<lpage>23</lpage>.<pub-id pub-id-type="doi">10.1016/j.semcdb.2015.01.015</pub-id><pub-id pub-id-type="pmid">25666262</pub-id></mixed-citation>
</ref>
<ref id="B59">
<label>59</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vince</surname><given-names>JE</given-names></name><name><surname>Wong</surname><given-names>WW</given-names></name><name><surname>Gentle</surname><given-names>I</given-names></name><name><surname>Lawlor</surname><given-names>KE</given-names></name><name><surname>Allam</surname><given-names>R</given-names></name><name><surname>O’Reilly</surname><given-names>L</given-names></name><etal></etal></person-group>
<article-title>Inhibitor of apoptosis proteins limit RIP3 kinase-dependent interleukin-1 activation</article-title>. <source/>Immunity (<year>2012</year>) <volume>36</volume>:<fpage>215</fpage>–<lpage>27</lpage>.<pub-id pub-id-type="doi">10.1016/j.immuni.2012.01.012</pub-id><pub-id pub-id-type="pmid">22365665</pub-id></mixed-citation>
</ref>
<ref id="B60">
<label>60</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Damgaard</surname><given-names>RB</given-names></name><name><surname>Fiil</surname><given-names>BK</given-names></name><name><surname>Speckmann</surname><given-names>C</given-names></name><name><surname>Yabal</surname><given-names>M</given-names></name><name><surname>zur Stadt</surname><given-names>U</given-names></name><name><surname>Bekker-Jensen</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Disease-causing mutations in the XIAP BIR2 domain impair NOD2-dependent immune signalling</article-title>. <source/>EMBO Mol Med (<year>2013</year>) <volume>5</volume>:<fpage>1278</fpage>–<lpage>95</lpage>.<pub-id pub-id-type="doi">10.1002/emmm.201303090</pub-id><pub-id pub-id-type="pmid">23818254</pub-id></mixed-citation>
</ref>
<ref id="B61">
<label>61</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krieg</surname><given-names>A</given-names></name><name><surname>Correa</surname><given-names>RG</given-names></name><name><surname>Garrison</surname><given-names>JB</given-names></name><name><surname>Le Negrate</surname><given-names>G</given-names></name><name><surname>Welsh</surname><given-names>K</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><etal></etal></person-group>
<article-title>XIAP mediates NOD signaling via interaction with RIP2</article-title>. <source/>Proc Natl Acad Sci U S A (<year>2009</year>) <volume>106</volume>:<fpage>14524</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.0907131106</pub-id><pub-id pub-id-type="pmid">19667203</pub-id></mixed-citation>
</ref>
<ref id="B62">
<label>62</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Speckmann</surname><given-names>C</given-names></name><name><surname>Lehmberg</surname><given-names>K</given-names></name><name><surname>Albert</surname><given-names>MH</given-names></name><name><surname>Damgaard</surname><given-names>RB</given-names></name><name><surname>Fritsch</surname><given-names>M</given-names></name><name><surname>Gyrd-Hansen</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>X-linked inhibitor of apoptosis (XIAP) deficiency: the spectrum of presenting manifestations beyond hemophagocytic lymphohistiocytosis</article-title>. <source/>Clin Immunol (<year>2013</year>) <volume>149</volume>:<fpage>133</fpage>–<lpage>41</lpage>.<pub-id pub-id-type="doi">10.1016/j.clim.2013.07.004</pub-id><pub-id pub-id-type="pmid">23973892</pub-id></mixed-citation>
</ref>
<ref id="B63">
<label>63</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguilar</surname><given-names>C</given-names></name><name><surname>Lenoir</surname><given-names>C</given-names></name><name><surname>Lambert</surname><given-names>N</given-names></name><name><surname>Begue</surname><given-names>B</given-names></name><name><surname>Brousse</surname><given-names>N</given-names></name><name><surname>Canioni</surname><given-names>D</given-names></name><etal></etal></person-group>
<article-title>Characterization of Crohn disease in X-linked inhibitor of apoptosis-deficient male patients and female symptomatic carriers</article-title>. <source/>J Allergy Clin Immunol (<year>2014</year>) <volume>134</volume>:<fpage>1131</fpage>–<lpage>41.e9</lpage>.<pub-id pub-id-type="doi">10.1016/j.jaci.2014.04.031</pub-id><pub-id pub-id-type="pmid">24942515</pub-id></mixed-citation>
</ref>
<ref id="B64">
<label>64</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Xiong</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Discovery of dual inhibitors of MDM2 and XIAP for cancer treatment</article-title>. <source/>Cancer Cell (<year>2016</year>) <volume>30</volume>:<fpage>623</fpage>–<lpage>36</lpage>.<pub-id pub-id-type="doi">10.1016/j.ccell.2016.08.015</pub-id><pub-id pub-id-type="pmid">27666947</pub-id></mixed-citation>
</ref>
<ref id="B65">
<label>65</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ammann</surname><given-names>S</given-names></name><name><surname>Elling</surname><given-names>R</given-names></name><name><surname>Gyrd-Hansen</surname><given-names>M</given-names></name><name><surname>Duckers</surname><given-names>G</given-names></name><name><surname>Bredius</surname><given-names>R</given-names></name><name><surname>Burns</surname><given-names>SO</given-names></name><etal></etal></person-group>
<article-title>A new functional assay for the diagnosis of X-linked inhibitor of apoptosis (XIAP) deficiency</article-title>. <source/>Clin Exp Immunol (<year>2014</year>) <volume>176</volume>:<fpage>394</fpage>–<lpage>400</lpage>.<pub-id pub-id-type="doi">10.1111/cei.12306</pub-id><pub-id pub-id-type="pmid">24611904</pub-id></mixed-citation>
</ref>
<ref id="B66">
<label>66</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huck</surname><given-names>K</given-names></name><name><surname>Feyen</surname><given-names>O</given-names></name><name><surname>Niehues</surname><given-names>T</given-names></name><name><surname>Ruschendorf</surname><given-names>F</given-names></name><name><surname>Hubner</surname><given-names>N</given-names></name><name><surname>Laws</surname><given-names>HJ</given-names></name><etal></etal></person-group>
<article-title>Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation</article-title>. <source/>J Clin Invest (<year>2009</year>) <volume>119</volume>:<fpage>1350</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1172/JCI37901</pub-id><pub-id pub-id-type="pmid">19425169</pub-id></mixed-citation>
</ref>
<ref id="B67">
<label>67</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linka</surname><given-names>RM</given-names></name><name><surname>Risse</surname><given-names>SL</given-names></name><name><surname>Bienemann</surname><given-names>K</given-names></name><name><surname>Werner</surname><given-names>M</given-names></name><name><surname>Linka</surname><given-names>Y</given-names></name><name><surname>Krux</surname><given-names>F</given-names></name><etal></etal></person-group>
<article-title>Loss-of-function mutations within the IL-2 inducible kinase ITK in patients with EBV-associated lymphoproliferative diseases</article-title>. <source/>Leukemia (<year>2012</year>) <volume>26</volume>:<fpage>963</fpage>–<lpage>71</lpage>.<pub-id pub-id-type="doi">10.1038/leu.2011.371</pub-id><pub-id pub-id-type="pmid">22289921</pub-id></mixed-citation>
</ref>
<ref id="B68">
<label>68</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mansouri</surname><given-names>D</given-names></name><name><surname>Mahdaviani</surname><given-names>SA</given-names></name><name><surname>Khalilzadeh</surname><given-names>S</given-names></name><name><surname>Mohajerani</surname><given-names>SA</given-names></name><name><surname>Hasanzad</surname><given-names>M</given-names></name><name><surname>Sadr</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>IL-2-inducible T-cell kinase deficiency with pulmonary manifestations due to disseminated Epstein-Barr virus infection</article-title>. <source/>Int Arch Allergy Immunol (<year>2012</year>) <volume>158</volume>:<fpage>418</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="doi">10.1159/000333472</pub-id><pub-id pub-id-type="pmid">22487848</pub-id></mixed-citation>
</ref>
<ref id="B69">
<label>69</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serwas</surname><given-names>NK</given-names></name><name><surname>Cagdas</surname><given-names>D</given-names></name><name><surname>Ban</surname><given-names>SA</given-names></name><name><surname>Bienemann</surname><given-names>K</given-names></name><name><surname>Salzer</surname><given-names>E</given-names></name><name><surname>Tezcan</surname><given-names>I</given-names></name><etal></etal></person-group>
<article-title>Identification of ITK deficiency as a novel genetic cause of idiopathic CD4+ T-cell lymphopenia</article-title>. <source/>Blood (<year>2014</year>) <volume>124</volume>:<fpage>655</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2014-03-564930</pub-id><pub-id pub-id-type="pmid">25061172</pub-id></mixed-citation>
</ref>
<ref id="B70">
<label>70</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cipe</surname><given-names>FE</given-names></name><name><surname>Aydogmus</surname><given-names>C</given-names></name><name><surname>Serwas</surname><given-names>NK</given-names></name><name><surname>Tugcu</surname><given-names>D</given-names></name><name><surname>Demirkaya</surname><given-names>M</given-names></name><name><surname>Bicici</surname><given-names>FA</given-names></name><etal></etal></person-group>
<article-title>ITK deficiency: how can EBV be treated before lymphoma?</article-title>
<source/>Pediatr Blood Cancer (<year>2015</year>) <volume>62</volume>:<fpage>2247</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1002/pbc.25648</pub-id><pub-id pub-id-type="pmid">26174447</pub-id></mixed-citation>
</ref>
<ref id="B71">
<label>71</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cagdas</surname><given-names>D</given-names></name><name><surname>Erman</surname><given-names>B</given-names></name><name><surname>Hanoglu</surname><given-names>D</given-names></name><name><surname>Tavil</surname><given-names>B</given-names></name><name><surname>Kuskonmaz</surname><given-names>B</given-names></name><name><surname>Aydin</surname><given-names>B</given-names></name><etal></etal></person-group>
<article-title>Course of IL-2-inducible T-cell kinase deficiency in a family: lymphomatoid granulomatosis, lymphoma and allogeneic bone marrow transplantation in one sibling; and death in the other</article-title>. <source/>Bone Marrow Transplant (<year>2017</year>) <volume>52</volume>:<fpage>126</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1038/bmt.2016.185</pub-id><pub-id pub-id-type="pmid">27454071</pub-id></mixed-citation>
</ref>
<ref id="B72">
<label>72</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stepensky</surname><given-names>P</given-names></name><name><surname>Weintraub</surname><given-names>M</given-names></name><name><surname>Yanir</surname><given-names>A</given-names></name><name><surname>Revel-Vilk</surname><given-names>S</given-names></name><name><surname>Krux</surname><given-names>F</given-names></name><name><surname>Huck</surname><given-names>K</given-names></name><etal></etal></person-group>
<article-title>IL-2-inducible T-cell kinase deficiency: clinical presentation and therapeutic approach</article-title>. <source/>Haematologica (<year>2011</year>) <volume>96</volume>:<fpage>472</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="doi">10.3324/haematol.2010.033910</pub-id><pub-id pub-id-type="pmid">21109689</pub-id></mixed-citation>
</ref>
<ref id="B73">
<label>73</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andreotti</surname><given-names>AH</given-names></name><name><surname>Schwartzberg</surname><given-names>PL</given-names></name><name><surname>Joseph</surname><given-names>RE</given-names></name><name><surname>Berg</surname><given-names>LJ</given-names></name></person-group>. <article-title>T-cell signaling regulated by the Tec family kinase, Itk</article-title>. <source/>Cold Spring Harb Perspect Biol (<year>2010</year>) <volume>2</volume>:<fpage>a002287</fpage>.<pub-id pub-id-type="doi">10.1101/cshperspect.a002287</pub-id><pub-id pub-id-type="pmid">20519342</pub-id></mixed-citation>
</ref>
<ref id="B74">
<label>74</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>KQ</given-names></name><name><surname>Bunnell</surname><given-names>SC</given-names></name><name><surname>Gurniak</surname><given-names>CB</given-names></name><name><surname>Berg</surname><given-names>LJ</given-names></name></person-group>. <article-title>T cell receptor-initiated calcium release is uncoupled from capacitative calcium entry in Itk-deficient T cells</article-title>. <source/>J Exp Med (<year>1998</year>) <volume>187</volume>:<fpage>1721</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1084/jem.187.10.1721</pub-id><pub-id pub-id-type="pmid">9584150</pub-id></mixed-citation>
</ref>
<ref id="B75">
<label>75</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>AM</given-names></name><name><surname>Mercer</surname><given-names>JC</given-names></name><name><surname>Iyer</surname><given-names>A</given-names></name><name><surname>Ragin</surname><given-names>MJ</given-names></name><name><surname>August</surname><given-names>A</given-names></name></person-group>. <article-title>Regulation of CXC chemokine receptor 4-mediated migration by the Tec family tyrosine kinase ITK</article-title>. <source/>J Biol Chem (<year>2004</year>) <volume>279</volume>:<fpage>29816</fpage>–<lpage>20</lpage>.<pub-id pub-id-type="doi">10.1074/jbc.M312848200</pub-id><pub-id pub-id-type="pmid">15123627</pub-id></mixed-citation>
</ref>
<ref id="B76">
<label>76</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schaeffer</surname><given-names>EM</given-names></name><name><surname>Debnath</surname><given-names>J</given-names></name><name><surname>Yap</surname><given-names>G</given-names></name><name><surname>McVicar</surname><given-names>D</given-names></name><name><surname>Liao</surname><given-names>XC</given-names></name><name><surname>Littman</surname><given-names>DR</given-names></name><etal></etal></person-group>
<article-title>Requirement for Tec kinases Rlk and Itk in T cell receptor signaling and immunity</article-title>. <source/>Science (<year>1999</year>) <volume>284</volume>:<fpage>638</fpage>–<lpage>41</lpage>.<pub-id pub-id-type="doi">10.1126/science.284.5414.638</pub-id><pub-id pub-id-type="pmid">10213685</pub-id></mixed-citation>
</ref>
<ref id="B77">
<label>77</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapnick</surname><given-names>SM</given-names></name><name><surname>Stinchcombe</surname><given-names>JC</given-names></name><name><surname>Griffiths</surname><given-names>GM</given-names></name><name><surname>Schwartzberg</surname><given-names>PL</given-names></name></person-group>
<article-title>Inducible T cell kinase regulates the acquisition of cytolytic capacity and degranulation in CD8(+) CTLs</article-title>. <source/>J Immunol (<year>2017</year>) <volume>198</volume>:<fpage>2699</fpage>–<lpage>711</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1601202</pub-id><pub-id pub-id-type="pmid">28213500</pub-id></mixed-citation>
</ref>
<ref id="B78">
<label>78</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>FY</given-names></name><name><surname>Chaigne-Delalande</surname><given-names>B</given-names></name><name><surname>Kanellopoulou</surname><given-names>C</given-names></name><name><surname>Davis</surname><given-names>JC</given-names></name><name><surname>Matthews</surname><given-names>HF</given-names></name><name><surname>Douek</surname><given-names>DC</given-names></name><etal></etal></person-group>
<article-title>Second messenger role for Mg2+ revealed by human T-cell immunodeficiency</article-title>. <source/>Nature (<year>2011</year>) <volume>475</volume>:<fpage>471</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1038/nature10246</pub-id><pub-id pub-id-type="pmid">21796205</pub-id></mixed-citation>
</ref>
<ref id="B79">
<label>79</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaigne-Delalande</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>FY</given-names></name><name><surname>O’Connor</surname><given-names>GM</given-names></name><name><surname>Lukacs</surname><given-names>MJ</given-names></name><name><surname>Jiang</surname><given-names>P</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><etal></etal></person-group>
<article-title>Mg2+ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D</article-title>. <source/>Science (<year>2013</year>) <volume>341</volume>:<fpage>186</fpage>–<lpage>91</lpage>.<pub-id pub-id-type="doi">10.1126/science.1240094</pub-id><pub-id pub-id-type="pmid">23846901</pub-id></mixed-citation>
</ref>
<ref id="B80">
<label>80</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brigida</surname><given-names>I</given-names></name><name><surname>Chiriaco</surname><given-names>M</given-names></name><name><surname>Di Cesare</surname><given-names>S</given-names></name><name><surname>Cittaro</surname><given-names>D</given-names></name><name><surname>Di Matteo</surname><given-names>G</given-names></name><name><surname>Giannelli</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Large deletion of MAGT1 gene in a patient with classic kaposi sarcoma, CD4 lymphopenia, and EBV infection</article-title>. <source/>J Clin Immunol (<year>2017</year>) <volume>37</volume>:<fpage>32</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1007/s10875-016-0341-y</pub-id><pub-id pub-id-type="pmid">27770395</pub-id></mixed-citation>
</ref>
<ref id="B81">
<label>81</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhalla</surname><given-names>F</given-names></name><name><surname>Murray</surname><given-names>S</given-names></name><name><surname>Sadler</surname><given-names>R</given-names></name><name><surname>Chaigne-Delalande</surname><given-names>B</given-names></name><name><surname>Sadaoka</surname><given-names>T</given-names></name><name><surname>Soilleux</surname><given-names>E</given-names></name><etal></etal></person-group>
<article-title>Identification of a novel mutation in MAGT1 and progressive multifocal leucoencephalopathy in a 58-year-old man with XMEN disease</article-title>. <source/>J Clin Immunol (<year>2015</year>) <volume>35</volume>:<fpage>112</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1007/s10875-014-0116-2</pub-id><pub-id pub-id-type="pmid">25504528</pub-id></mixed-citation>
</ref>
<ref id="B82">
<label>82</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patiroglu</surname><given-names>T</given-names></name><name><surname>Haluk Akar</surname><given-names>H</given-names></name><name><surname>Gilmour</surname><given-names>K</given-names></name><name><surname>Unal</surname><given-names>E</given-names></name><name><surname>Akif Ozdemir</surname><given-names>M</given-names></name><name><surname>Bibi</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>A case of XMEN syndrome presented with severe auto-immune disorders mimicking autoimmune lymphoproliferative disease</article-title>. <source/>Clin Immunol (<year>2015</year>) <volume>159</volume>:<fpage>58</fpage>–<lpage>62</lpage>.<pub-id pub-id-type="doi">10.1016/j.clim.2015.04.015</pub-id><pub-id pub-id-type="pmid">25956530</pub-id></mixed-citation>
</ref>
<ref id="B83">
<label>83</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>FY</given-names></name><name><surname>Chaigne-Delalande</surname><given-names>B</given-names></name><name><surname>Su</surname><given-names>H</given-names></name><name><surname>Uzel</surname><given-names>G</given-names></name><name><surname>Matthews</surname><given-names>H</given-names></name><name><surname>Lenardo</surname><given-names>MJ</given-names></name></person-group>. <article-title>XMEN disease: a new primary immunodeficiency affecting Mg2+ regulation of immunity against Epstein-Barr virus</article-title>. <source/>Blood (<year>2014</year>) <volume>123</volume>:<fpage>2148</fpage>–<lpage>52</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2013-11-538686</pub-id><pub-id pub-id-type="pmid">24550228</pub-id></mixed-citation>
</ref>
<ref id="B84">
<label>84</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cherepanova</surname><given-names>N</given-names></name><name><surname>Shrimal</surname><given-names>S</given-names></name><name><surname>Gilmore</surname><given-names>R</given-names></name></person-group>. <article-title>N-linked glycosylation and homeostasis of the endoplasmic reticulum</article-title>. <source/>Curr Opin Cell Biol (<year>2016</year>) <volume>41</volume>:<fpage>57</fpage>–<lpage>65</lpage>.<pub-id pub-id-type="doi">10.1016/j.ceb.2016.03.021</pub-id><pub-id pub-id-type="pmid">27085638</pub-id></mixed-citation>
</ref>
<ref id="B85">
<label>85</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>FY</given-names></name><name><surname>Lenardo</surname><given-names>MJ</given-names></name><name><surname>Chaigne-Delalande</surname><given-names>B</given-names></name></person-group>. <article-title>Loss of MAGT1 abrogates the Mg2+ flux required for T cell signaling and leads to a novel human primary immunodeficiency</article-title>. <source/>Magnes Res (<year>2011</year>) <volume>24</volume>:<fpage>S109</fpage>–<lpage>14</lpage>.<pub-id pub-id-type="doi">10.1684/mrh.2011.0286</pub-id><pub-id pub-id-type="pmid">21983175</pub-id></mixed-citation>
</ref>
<ref id="B86">
<label>86</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gotru</surname><given-names>SK</given-names></name><name><surname>Gil-Pulido</surname><given-names>J</given-names></name><name><surname>Beyersdorf</surname><given-names>N</given-names></name><name><surname>Diefenbach</surname><given-names>A</given-names></name><name><surname>Becker</surname><given-names>IC</given-names></name><name><surname>Vogtle</surname><given-names>T</given-names></name><etal></etal></person-group>
<article-title>Cutting edge: imbalanced cation homeostasis in MAGT1-deficient B Cells dysregulates B cell development and signaling in mice</article-title>. <source/>J Immunol (<year>2018</year>) <volume>200</volume>(<issue>8</issue>):<fpage>2529</fpage>–<lpage>34</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1701467</pub-id><pub-id pub-id-type="pmid">29581357</pub-id></mixed-citation>
</ref>
<ref id="B87">
<label>87</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pappworth</surname><given-names>IY</given-names></name><name><surname>Wang</surname><given-names>EC</given-names></name><name><surname>Rowe</surname><given-names>M</given-names></name></person-group>. <article-title>The switch from latent to productive infection in Epstein-Barr virus-infected B cells is associated with sensitization to NK cell killing</article-title>. <source/>J Virol (<year>2007</year>) <volume>81</volume>:<fpage>474</fpage>–<lpage>82</lpage>.<pub-id pub-id-type="doi">10.1128/JVI.01777-06</pub-id><pub-id pub-id-type="pmid">17079298</pub-id></mixed-citation>
</ref>
<ref id="B88">
<label>88</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Obeidy</surname><given-names>P</given-names></name><name><surname>Sharland</surname><given-names>AF</given-names></name></person-group>. <article-title>NKG2D and its ligands</article-title>. <source/>Int J Biochem Cell Biol (<year>2009</year>) <volume>41</volume>:<fpage>2364</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1016/j.biocel.2009.07.005</pub-id><pub-id pub-id-type="pmid">19631280</pub-id></mixed-citation>
</ref>
<ref id="B89">
<label>89</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Montfrans</surname><given-names>JM</given-names></name><name><surname>Hoepelman</surname><given-names>AI</given-names></name><name><surname>Otto</surname><given-names>S</given-names></name><name><surname>van Gijn</surname><given-names>M</given-names></name><name><surname>van de Corput</surname><given-names>L</given-names></name><name><surname>de Weger</surname><given-names>RA</given-names></name><etal></etal></person-group>
<article-title>CD27 deficiency is associated with combined immunodeficiency and persistent symptomatic EBV viremia</article-title>. <source/>J Allergy Clin Immunol (<year>2012</year>) <volume>129</volume>:<fpage>787</fpage>–<lpage>93.e6</lpage>.<pub-id pub-id-type="doi">10.1016/j.jaci.2011.11.013</pub-id><pub-id pub-id-type="pmid">22197273</pub-id></mixed-citation>
</ref>
<ref id="B90">
<label>90</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alkhairy</surname><given-names>OK</given-names></name><name><surname>Perez-Becker</surname><given-names>R</given-names></name><name><surname>Driessen</surname><given-names>GJ</given-names></name><name><surname>Abolhassani</surname><given-names>H</given-names></name><name><surname>van Montfrans</surname><given-names>J</given-names></name><name><surname>Borte</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Novel mutations in TNFRSF7/CD27: clinical, immunologic, and genetic characterization of human CD27 deficiency</article-title>. <source/>J Allergy Clin Immunol (<year>2015</year>) <volume>136</volume>:<fpage>703</fpage>–<lpage>12.e10</lpage>.<pub-id pub-id-type="doi">10.1016/j.jaci.2015.02.022</pub-id><pub-id pub-id-type="pmid">25843314</pub-id></mixed-citation>
</ref>
<ref id="B91">
<label>91</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Izawa</surname><given-names>K</given-names></name><name><surname>Martin</surname><given-names>E</given-names></name><name><surname>Soudais</surname><given-names>C</given-names></name><name><surname>Bruneau</surname><given-names>J</given-names></name><name><surname>Boutboul</surname><given-names>D</given-names></name><name><surname>Rodriguez</surname><given-names>R</given-names></name><etal></etal></person-group>
<article-title>Inherited CD70 deficiency in humans reveals a critical role for the CD70-CD27 pathway in immunity to Epstein-Barr virus infection</article-title>. <source/>J Exp Med (<year>2017</year>) <volume>214</volume>:<fpage>73</fpage>–<lpage>89</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20160784</pub-id><pub-id pub-id-type="pmid">28011863</pub-id></mixed-citation>
</ref>
<ref id="B92">
<label>92</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salzer</surname><given-names>E</given-names></name><name><surname>Daschkey</surname><given-names>S</given-names></name><name><surname>Choo</surname><given-names>S</given-names></name><name><surname>Gombert</surname><given-names>M</given-names></name><name><surname>Santos-Valente</surname><given-names>E</given-names></name><name><surname>Ginzel</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Combined immunodeficiency with life-threatening EBV-associated lymphoproliferative disorder in patients lacking functional CD27</article-title>. <source/>Haematologica (<year>2013</year>) <volume>98</volume>:<fpage>473</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.3324/haematol.2012.068791</pub-id><pub-id pub-id-type="pmid">22801960</pub-id></mixed-citation>
</ref>
<ref id="B93">
<label>93</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>U</given-names></name><name><surname>Rajewsky</surname><given-names>K</given-names></name><name><surname>Kuppers</surname><given-names>R</given-names></name></person-group>. <article-title>Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells</article-title>. <source/>J Exp Med (<year>1998</year>) <volume>188</volume>:<fpage>1679</fpage>–<lpage>89</lpage>.<pub-id pub-id-type="doi">10.1084/jem.188.9.1679</pub-id><pub-id pub-id-type="pmid">9802980</pub-id></mixed-citation>
</ref>
<ref id="B94">
<label>94</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobs</surname><given-names>J</given-names></name><name><surname>Deschoolmeester</surname><given-names>V</given-names></name><name><surname>Zwaenepoel</surname><given-names>K</given-names></name><name><surname>Rolfo</surname><given-names>C</given-names></name><name><surname>Silence</surname><given-names>K</given-names></name><name><surname>Rottey</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>CD70: an emerging target in cancer immunotherapy</article-title>. <source/>Pharmacol Ther (<year>2015</year>) <volume>155</volume>:<fpage>1</fpage>–<lpage>10</lpage>.<pub-id pub-id-type="doi">10.1016/j.pharmthera.2015.07.007</pub-id><pub-id pub-id-type="pmid">26213107</pub-id></mixed-citation>
</ref>
<ref id="B95">
<label>95</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tangye</surname><given-names>SG</given-names></name><name><surname>Liu</surname><given-names>YJ</given-names></name><name><surname>Aversa</surname><given-names>G</given-names></name><name><surname>Phillips</surname><given-names>JH</given-names></name><name><surname>de Vries</surname><given-names>JE</given-names></name></person-group>. <article-title>Identification of functional human splenic memory B cells by expression of CD148 and CD27</article-title>. <source/>J Exp Med (<year>1998</year>) <volume>188</volume>:<fpage>1691</fpage>–<lpage>703</lpage>.<pub-id pub-id-type="doi">10.1084/jem.188.9.1691</pub-id><pub-id pub-id-type="pmid">9802981</pub-id></mixed-citation>
</ref>
<ref id="B96">
<label>96</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hendriks</surname><given-names>J</given-names></name><name><surname>Gravestein</surname><given-names>LA</given-names></name><name><surname>Tesselaar</surname><given-names>K</given-names></name><name><surname>van Lier</surname><given-names>RA</given-names></name><name><surname>Schumacher</surname><given-names>TN</given-names></name><name><surname>Borst</surname><given-names>J</given-names></name></person-group>. <article-title>CD27 is required for generation and long-term maintenance of T cell immunity</article-title>. <source/>Nat Immunol (<year>2000</year>) <volume>1</volume>:<fpage>433</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="doi">10.1038/80877</pub-id><pub-id pub-id-type="pmid">11062504</pub-id></mixed-citation>
</ref>
<ref id="B97">
<label>97</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borst</surname><given-names>J</given-names></name><name><surname>Hendriks</surname><given-names>J</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name></person-group>. <article-title>CD27 and CD70 in T cell and B cell activation</article-title>. <source/>Curr Opin Immunol (<year>2005</year>) <volume>17</volume>:<fpage>275</fpage>–<lpage>81</lpage>.<pub-id pub-id-type="doi">10.1016/j.coi.2005.04.004</pub-id><pub-id pub-id-type="pmid">15886117</pub-id></mixed-citation>
</ref>
<ref id="B98">
<label>98</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abolhassani</surname><given-names>H</given-names></name><name><surname>Edwards</surname><given-names>ES</given-names></name><name><surname>Ikinciogullari</surname><given-names>A</given-names></name><name><surname>Jing</surname><given-names>H</given-names></name><name><surname>Borte</surname><given-names>S</given-names></name><name><surname>Buggert</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Combined immunodeficiency and Epstein-Barr virus-induced B cell malignancy in humans with inherited CD70 deficiency</article-title>. <source/>J Exp Med (<year>2017</year>) <volume>214</volume>:<fpage>91</fpage>–<lpage>106</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20160849</pub-id><pub-id pub-id-type="pmid">28011864</pub-id></mixed-citation>
</ref>
<ref id="B99">
<label>99</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caorsi</surname><given-names>R</given-names></name><name><surname>Rusmini</surname><given-names>M</given-names></name><name><surname>Volpi</surname><given-names>S</given-names></name><name><surname>Chiesa</surname><given-names>S</given-names></name><name><surname>Pastorino</surname><given-names>C</given-names></name><name><surname>Sementa</surname><given-names>AR</given-names></name><etal></etal></person-group>
<article-title>CD70 deficiency due to a novel mutation in a patient with severe chronic EBV infection presenting as a periodic fever</article-title>. <source/>Front Immunol (<year>2017</year>) <volume>8</volume>:<fpage>2015</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2017.02015</pub-id><pub-id pub-id-type="pmid">29434583</pub-id></mixed-citation>
</ref>
<ref id="B100">
<label>100</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>E</given-names></name><name><surname>Palmic</surname><given-names>N</given-names></name><name><surname>Sanquer</surname><given-names>S</given-names></name><name><surname>Lenoir</surname><given-names>C</given-names></name><name><surname>Hauck</surname><given-names>F</given-names></name><name><surname>Mongellaz</surname><given-names>C</given-names></name><etal></etal></person-group>
<article-title>CTP synthase 1 deficiency in humans reveals its central role in lymphocyte proliferation</article-title>. <source/>Nature (<year>2014</year>) <volume>510</volume>:<fpage>288</fpage>–<lpage>92</lpage>.<pub-id pub-id-type="doi">10.1038/nature13386</pub-id><pub-id pub-id-type="pmid">24870241</pub-id></mixed-citation>
</ref>
<ref id="B101">
<label>101</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kucuk</surname><given-names>ZY</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Filipovich</surname><given-names>L</given-names></name><name><surname>Bleesing</surname><given-names>JJ</given-names></name></person-group>
<article-title>CTP synthase 1 deficiency in successfully transplanted siblings with combined immune deficiency and chronic active EBV infection</article-title>. <source/>J Clin Immunol (<year>2016</year>) <volume>36</volume>:<fpage>750</fpage>–<lpage>3</lpage>.<pub-id pub-id-type="doi">10.1007/s10875-016-0332-z</pub-id><pub-id pub-id-type="pmid">27638562</pub-id></mixed-citation>
</ref>
<ref id="B102">
<label>102</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Truck</surname><given-names>J</given-names></name><name><surname>Kelly</surname><given-names>DF</given-names></name><name><surname>Taylor</surname><given-names>JM</given-names></name><name><surname>Kienzler</surname><given-names>AK</given-names></name><name><surname>Lester</surname><given-names>T</given-names></name><name><surname>Seller</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Variable phenotype and discrete alterations of immune phenotypes in CTP synthase 1 deficiency: report of 2 siblings</article-title>. <source/>J Allergy Clin Immunol (<year>2016</year>) <volume>138</volume>:<fpage>1722</fpage>–<lpage>5.e6</lpage>.<pub-id pub-id-type="doi">10.1016/j.jaci.2016.04.059</pub-id><pub-id pub-id-type="pmid">27543071</pub-id></mixed-citation>
</ref>
<ref id="B103">
<label>103</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>DR</given-names></name><name><surname>Guy</surname><given-names>HI</given-names></name></person-group>
<article-title>Mammalian pyrimidine biosynthesis: fresh insights into an ancient pathway</article-title>. <source/>J Biol Chem (<year>2004</year>) <volume>279</volume>:<fpage>33035</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1074/jbc.R400007200</pub-id><pub-id pub-id-type="pmid">15096496</pub-id></mixed-citation>
</ref>
<ref id="B104">
<label>104</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stray-Pedersen</surname><given-names>A</given-names></name><name><surname>Jouanguy</surname><given-names>E</given-names></name><name><surname>Crequer</surname><given-names>A</given-names></name><name><surname>Bertuch</surname><given-names>AA</given-names></name><name><surname>Brown</surname><given-names>BS</given-names></name><name><surname>Jhangiani</surname><given-names>SN</given-names></name><etal></etal></person-group>
<article-title>Compound heterozygous CORO1A mutations in siblings with a mucocutaneous-immunodeficiency syndrome of epidermodysplasia verruciformis-HPV, molluscum contagiosum and granulomatous tuberculoid leprosy</article-title>. <source/>J Clin Immunol (<year>2014</year>) <volume>34</volume>:<fpage>871</fpage>–<lpage>90</lpage>.<pub-id pub-id-type="doi">10.1007/s10875-014-0074-8</pub-id><pub-id pub-id-type="pmid">25073507</pub-id></mixed-citation>
</ref>
<ref id="B105">
<label>105</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiow</surname><given-names>LR</given-names></name><name><surname>Roadcap</surname><given-names>DW</given-names></name><name><surname>Paris</surname><given-names>K</given-names></name><name><surname>Watson</surname><given-names>SR</given-names></name><name><surname>Grigorova</surname><given-names>IL</given-names></name><name><surname>Lebet</surname><given-names>T</given-names></name><etal></etal></person-group>
<article-title>The actin regulator coronin 1A is mutant in a thymic egress-deficient mouse strain and in a patient with severe combined immunodeficiency</article-title>. <source/>Nat Immunol (<year>2008</year>) <volume>9</volume>:<fpage>1307</fpage>–<lpage>15</lpage>.<pub-id pub-id-type="doi">10.1038/ni.1662</pub-id><pub-id pub-id-type="pmid">18836449</pub-id></mixed-citation>
</ref>
<ref id="B106">
<label>106</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moshous</surname><given-names>D</given-names></name><name><surname>Martin</surname><given-names>E</given-names></name><name><surname>Carpentier</surname><given-names>W</given-names></name><name><surname>Lim</surname><given-names>A</given-names></name><name><surname>Callebaut</surname><given-names>I</given-names></name><name><surname>Canioni</surname><given-names>D</given-names></name><etal></etal></person-group>
<article-title>Whole-exome sequencing identifies coronin-1A deficiency in 3 siblings with immunodeficiency and EBV-associated B-cell lymphoproliferation</article-title>. <source/>J Allergy Clin Immunol (<year>2013</year>) <volume>131</volume>:<fpage>1594</fpage>–<lpage>603</lpage>.<pub-id pub-id-type="doi">10.1016/j.jaci.2013.01.042</pub-id><pub-id pub-id-type="pmid">23522482</pub-id></mixed-citation>
</ref>
<ref id="B107">
<label>107</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Punwani</surname><given-names>D</given-names></name><name><surname>Pelz</surname><given-names>B</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Arva</surname><given-names>NC</given-names></name><name><surname>Schafernak</surname><given-names>K</given-names></name><name><surname>Kondratowicz</surname><given-names>K</given-names></name><etal></etal></person-group>
<article-title>Coronin-1A: immune deficiency in humans and mice</article-title>. <source/>J Clin Immunol (<year>2015</year>) <volume>35</volume>:<fpage>100</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1007/s10875-015-0130-z</pub-id><pub-id pub-id-type="pmid">25666293</pub-id></mixed-citation>
</ref>
<ref id="B108">
<label>108</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yee</surname><given-names>CS</given-names></name><name><surname>Massaad</surname><given-names>MJ</given-names></name><name><surname>Bainter</surname><given-names>W</given-names></name><name><surname>Ohsumi</surname><given-names>TK</given-names></name><name><surname>Foger</surname><given-names>N</given-names></name><name><surname>Chan</surname><given-names>AC</given-names></name><etal></etal></person-group>
<article-title>Recurrent viral infections associated with a homozygous CORO1A mutation that disrupts oligomerization and cytoskeletal association</article-title>. <source/>J Allergy Clin Immunol (<year>2016</year>) <volume>137</volume>:<fpage>879</fpage>–<lpage>88.e2</lpage>.<pub-id pub-id-type="doi">10.1016/j.jaci.2015.08.020</pub-id><pub-id pub-id-type="pmid">26476480</pub-id></mixed-citation>
</ref>
<ref id="B109">
<label>109</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moshous</surname><given-names>D</given-names></name><name><surname>de Villartay</surname><given-names>JP</given-names></name></person-group>. <article-title>The expanding spectrum of human coronin 1A deficiency</article-title>. <source/>Curr Allergy Asthma Rep (<year>2014</year>) <volume>14</volume>:<fpage>481</fpage>.<pub-id pub-id-type="doi">10.1007/s11882-014-0481-1</pub-id><pub-id pub-id-type="pmid">25269405</pub-id></mixed-citation>
</ref>
<ref id="B110">
<label>110</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pieters</surname><given-names>J</given-names></name><name><surname>Muller</surname><given-names>P</given-names></name><name><surname>Jayachandran</surname><given-names>R</given-names></name></person-group>. <article-title>On guard: coronin proteins in innate and adaptive immunity</article-title>. <source/>Nat Rev Immunol (<year>2013</year>) <volume>13</volume>:<fpage>510</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1038/nri3465</pub-id><pub-id pub-id-type="pmid">23765056</pub-id></mixed-citation>
</ref>
<ref id="B111">
<label>111</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foger</surname><given-names>N</given-names></name><name><surname>Rangell</surname><given-names>L</given-names></name><name><surname>Danilenko</surname><given-names>DM</given-names></name><name><surname>Chan</surname><given-names>AC</given-names></name></person-group>. <article-title>Requirement for coronin 1 in T lymphocyte trafficking and cellular homeostasis</article-title>. <source/>Science (<year>2006</year>) <volume>313</volume>:<fpage>839</fpage>–<lpage>42</lpage>.<pub-id pub-id-type="doi">10.1126/science.1130563</pub-id><pub-id pub-id-type="pmid">16902139</pub-id></mixed-citation>
</ref>
<ref id="B112">
<label>112</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mueller</surname><given-names>P</given-names></name><name><surname>Massner</surname><given-names>J</given-names></name><name><surname>Jayachandran</surname><given-names>R</given-names></name><name><surname>Combaluzier</surname><given-names>B</given-names></name><name><surname>Albrecht</surname><given-names>I</given-names></name><name><surname>Gatfield</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Regulation of T cell survival through coronin-1-mediated generation of inositol-1,4,5-trisphosphate and calcium mobilization after T cell receptor triggering</article-title>. <source/>Nat Immunol (<year>2008</year>) <volume>9</volume>:<fpage>424</fpage>–<lpage>31</lpage>.<pub-id pub-id-type="doi">10.1038/ni1570</pub-id><pub-id pub-id-type="pmid">18345003</pub-id></mixed-citation>
</ref>
<ref id="B113">
<label>113</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mace</surname><given-names>EM</given-names></name><name><surname>Orange</surname><given-names>JS</given-names></name></person-group>. <article-title>Lytic immune synapse function requires filamentous actin deconstruction by coronin 1A</article-title>. <source/>Proc Natl Acad Sci U S A (<year>2014</year>) <volume>111</volume>:<fpage>6708</fpage>–<lpage>13</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.1314975111</pub-id><pub-id pub-id-type="pmid">24760828</pub-id></mixed-citation>
</ref>
<ref id="B114">
<label>114</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaminski</surname><given-names>S</given-names></name><name><surname>Hermann-Kleiter</surname><given-names>N</given-names></name><name><surname>Meisel</surname><given-names>M</given-names></name><name><surname>Thuille</surname><given-names>N</given-names></name><name><surname>Cronin</surname><given-names>S</given-names></name><name><surname>Hara</surname><given-names>H</given-names></name><etal></etal></person-group>
<article-title>Coronin 1A is an essential regulator of the TGFbeta receptor/SMAD3 signaling pathway in Th17 CD4(+) T cells</article-title>. <source/>J Autoimmun (<year>2011</year>) <volume>37</volume>:<fpage>198</fpage>–<lpage>208</lpage>.<pub-id pub-id-type="doi">10.1016/j.jaut.2011.05.018</pub-id><pub-id pub-id-type="pmid">21700422</pub-id></mixed-citation>
</ref>
<ref id="B115">
<label>115</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegmund</surname><given-names>K</given-names></name><name><surname>Thuille</surname><given-names>N</given-names></name><name><surname>Posch</surname><given-names>N</given-names></name><name><surname>Fresser</surname><given-names>F</given-names></name><name><surname>Baier</surname><given-names>G</given-names></name></person-group>
<article-title>Novel protein kinase C theta: coronin 1A complex in T lymphocytes</article-title>. <source/>Cell Commun Signal (<year>2015</year>) <volume>13</volume>:<fpage>22</fpage><pub-id pub-id-type="doi">10.1186/s12964-015-0100-3</pub-id><pub-id pub-id-type="pmid">25889880</pub-id></mixed-citation>
</ref>
<ref id="B116">
<label>116</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jayachandran</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Bosedasgupta</surname><given-names>S</given-names></name><name><surname>Muller</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>CL</given-names></name><name><surname>Moshous</surname><given-names>D</given-names></name><etal></etal></person-group>
<article-title>Coronin 1 regulates cognition and behavior through modulation of cAMP/protein kinase A signaling</article-title>. <source/>PLoS Biol (<year>2014</year>) <volume>12</volume>:<fpage>e1001820</fpage>.<pub-id pub-id-type="doi">10.1371/journal.pbio.1001820</pub-id><pub-id pub-id-type="pmid">24667537</pub-id></mixed-citation>
</ref>
<ref id="B117">
<label>117</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pick</surname><given-names>R</given-names></name><name><surname>Begandt</surname><given-names>D</given-names></name><name><surname>Stocker</surname><given-names>TJ</given-names></name><name><surname>Salvermoser</surname><given-names>M</given-names></name><name><surname>Thome</surname><given-names>S</given-names></name><name><surname>Bottcher</surname><given-names>RT</given-names></name><etal></etal></person-group>
<article-title>Coronin 1A, a novel player in integrin biology, controls neutrophil trafficking in innate immunity</article-title>. <source/>Blood (<year>2017</year>) <volume>130</volume>:<fpage>847</fpage>–<lpage>58</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2016-11-749622</pub-id><pub-id pub-id-type="pmid">28615221</pub-id></mixed-citation>
</ref>
<ref id="B118">
<label>118</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leiding</surname><given-names>JW</given-names></name><name><surname>Holland</surname><given-names>SM</given-names></name></person-group>. <article-title>Warts and all: human papillomavirus in primary immunodeficiencies</article-title>. <source/>J Allergy Clin Immunol (<year>2012</year>) <volume>130</volume>:<fpage>1030</fpage>–<lpage>48</lpage>.<pub-id pub-id-type="doi">10.1016/j.jaci.2012.07.049</pub-id><pub-id pub-id-type="pmid">23036745</pub-id></mixed-citation>
</ref>
<ref id="B119">
<label>119</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winter</surname><given-names>S</given-names></name><name><surname>Martin</surname><given-names>E</given-names></name><name><surname>Boutboul</surname><given-names>D</given-names></name><name><surname>Lenoir</surname><given-names>C</given-names></name><name><surname>Boudjemaa</surname><given-names>S</given-names></name><name><surname>Petit</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Loss of RASGRP1 in humans impairs T-cell expansion leading to Epstein-Barr virus susceptibility</article-title>. <source/>EMBO Mol Med (<year>2018</year>) <volume>10</volume>(<issue>2</issue>):<fpage>188</fpage>–<lpage>99</lpage>.<pub-id pub-id-type="doi">10.15252/emmm.201708292</pub-id><pub-id pub-id-type="pmid">29282224</pub-id></mixed-citation>
</ref>
<ref id="B120">
<label>120</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salzer</surname><given-names>E</given-names></name><name><surname>Cagdas</surname><given-names>D</given-names></name><name><surname>Hons</surname><given-names>M</given-names></name><name><surname>Mace</surname><given-names>EM</given-names></name><name><surname>Garncarz</surname><given-names>W</given-names></name><name><surname>Petronczki</surname><given-names>OY</given-names></name><etal></etal></person-group>
<article-title>RASGRP1 deficiency causes immunodeficiency with impaired cytoskeletal dynamics</article-title>. <source/>Nat Immunol (<year>2016</year>) <volume>17</volume>:<fpage>1352</fpage>–<lpage>60</lpage>.<pub-id pub-id-type="doi">10.1038/ni.3575</pub-id><pub-id pub-id-type="pmid">27776107</pub-id></mixed-citation>
</ref>
<ref id="B121">
<label>121</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Platt</surname><given-names>CD</given-names></name><name><surname>Fried</surname><given-names>AJ</given-names></name><name><surname>Hoyos-Bachiloglu</surname><given-names>R</given-names></name><name><surname>Usmani</surname><given-names>GN</given-names></name><name><surname>Schmidt</surname><given-names>B</given-names></name><name><surname>Whangbo</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Combined immunodeficiency with EBV positive B cell lymphoma and epidermodysplasia verruciformis due to a novel homozygous mutation in RASGRP1</article-title>. <source/>Clin Immunol (<year>2017</year>) <volume>183</volume>:<fpage>142</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1016/j.clim.2017.08.007</pub-id><pub-id pub-id-type="pmid">28822832</pub-id></mixed-citation>
</ref>
<ref id="B122">
<label>122</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kortum</surname><given-names>RL</given-names></name><name><surname>Rouquette-Jazdanian</surname><given-names>AK</given-names></name><name><surname>Samelson</surname><given-names>LE</given-names></name></person-group>. <article-title>Ras and extracellular signal-regulated kinase signaling in thymocytes and T cells</article-title>. <source/>Trends Immunol (<year>2013</year>) <volume>34</volume>:<fpage>259</fpage>–<lpage>68</lpage>.<pub-id pub-id-type="doi">10.1016/j.it.2013.02.004</pub-id><pub-id pub-id-type="pmid">23506953</pub-id></mixed-citation>
</ref>
<ref id="B123">
<label>123</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hogquist</surname><given-names>K</given-names></name></person-group>
<article-title>RasGRP: the missing link for Ras activation in thymocytes</article-title>. <source/>Trends Immunol (<year>2001</year>) <volume>22</volume>:<fpage>69</fpage><pub-id pub-id-type="doi">10.1016/S1471-4906(00)01845-7</pub-id></mixed-citation>
</ref>
<ref id="B124">
<label>124</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roose</surname><given-names>JP</given-names></name><name><surname>Mollenauer</surname><given-names>M</given-names></name><name><surname>Gupta</surname><given-names>VA</given-names></name><name><surname>Stone</surname><given-names>J</given-names></name><name><surname>Weiss</surname><given-names>A</given-names></name></person-group>. <article-title>A diacylglycerol-protein kinase C-RasGRP1 pathway directs Ras activation upon antigen receptor stimulation of T cells</article-title>. <source/>Mol Cell Biol (<year>2005</year>) <volume>25</volume>:<fpage>4426</fpage>–<lpage>41</lpage>.<pub-id pub-id-type="doi">10.1128/MCB.25.11.4426-4441.2005</pub-id><pub-id pub-id-type="pmid">15899849</pub-id></mixed-citation>
</ref>
<ref id="B125">
<label>125</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warnecke</surname><given-names>N</given-names></name><name><surname>Poltorak</surname><given-names>M</given-names></name><name><surname>Kowtharapu</surname><given-names>BS</given-names></name><name><surname>Arndt</surname><given-names>B</given-names></name><name><surname>Stone</surname><given-names>JC</given-names></name><name><surname>Schraven</surname><given-names>B</given-names></name><etal></etal></person-group>
<article-title>TCR-mediated Erk activation does not depend on Sos and Grb2 in peripheral human T cells</article-title>. <source/>EMBO Rep (<year>2012</year>) <volume>13</volume>:<fpage>386</fpage>–<lpage>91</lpage>.<pub-id pub-id-type="doi">10.1038/embor.2012.17</pub-id><pub-id pub-id-type="pmid">22344067</pub-id></mixed-citation>
</ref>
<ref id="B126">
<label>126</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Latour</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Winter</surname><given-names>S</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>RASGRP1 mutation in autoimmune lymphoproliferative syndrome-like disease</article-title>. <source/>J Allergy Clin Immunol (<year>2017</year>).<pub-id pub-id-type="doi">10.1016/j.jaci.2017.10.026</pub-id><pub-id pub-id-type="pmid">29155103</pub-id></mixed-citation>
</ref>
<ref id="B127">
<label>127</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartlett</surname><given-names>A</given-names></name><name><surname>Buhlmann</surname><given-names>JE</given-names></name><name><surname>Stone</surname><given-names>J</given-names></name><name><surname>Lim</surname><given-names>B</given-names></name><name><surname>Barrington</surname><given-names>RA</given-names></name></person-group>. <article-title>Multiple checkpoint breach of B cell tolerance in Rasgrp1-deficient mice</article-title>. <source/>J Immunol (<year>2013</year>) <volume>191</volume>:<fpage>3605</fpage>–<lpage>13</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1202892</pub-id><pub-id pub-id-type="pmid">23997211</pub-id></mixed-citation>
</ref>
<ref id="B128">
<label>128</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daley</surname><given-names>SR</given-names></name><name><surname>Coakley</surname><given-names>KM</given-names></name><name><surname>Hu</surname><given-names>DY</given-names></name><name><surname>Randall</surname><given-names>KL</given-names></name><name><surname>Jenne</surname><given-names>CN</given-names></name><name><surname>Limnander</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>Rasgrp1 mutation increases naive T-cell CD44 expression and drives mTOR-dependent accumulation of Helios(+) T cells and autoantibodies</article-title>. <source/>Elife (<year>2013</year>) <volume>2</volume>:<fpage>e01020</fpage><pub-id pub-id-type="doi">10.7554/eLife.01020</pub-id><pub-id pub-id-type="pmid">24336796</pub-id></mixed-citation>
</ref>
<ref id="B129">
<label>129</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Molineros</surname><given-names>JE</given-names></name><name><surname>Looger</surname><given-names>LL</given-names></name><name><surname>Zhou</surname><given-names>XJ</given-names></name><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Okada</surname><given-names>Y</given-names></name><etal></etal></person-group>
<article-title>High-density genotyping of immune-related loci identifies new SLE risk variants in individuals with Asian ancestry</article-title>. <source/>Nat Genet (<year>2016</year>) <volume>48</volume>:<fpage>323</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="doi">10.1038/ng.3496</pub-id><pub-id pub-id-type="pmid">26808113</pub-id></mixed-citation>
</ref>
<ref id="B130">
<label>130</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>XJ</given-names></name><name><surname>Nath</surname><given-names>SK</given-names></name><name><surname>Qi</surname><given-names>YY</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Hou</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>YM</given-names></name><etal></etal></person-group>
<article-title>Novel identified associations of RGS1 and RASGRP1 variants in IgA nephropathy</article-title>. <source/>Sci Rep (<year>2016</year>) <volume>6</volume>:<fpage>35781</fpage>.<pub-id pub-id-type="doi">10.1038/srep35781</pub-id><pub-id pub-id-type="pmid">27804980</pub-id></mixed-citation>
</ref>
<ref id="B131">
<label>131</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qu</surname><given-names>HQ</given-names></name><name><surname>Grant</surname><given-names>SF</given-names></name><name><surname>Bradfield</surname><given-names>JP</given-names></name><name><surname>Kim</surname><given-names>C</given-names></name><name><surname>Frackelton</surname><given-names>E</given-names></name><name><surname>Hakonarson</surname><given-names>H</given-names></name><etal></etal></person-group>
<article-title>Association of RASGRP1 with type 1 diabetes is revealed by combined follow-up of two genome-wide studies</article-title>. <source/>J Med Genet (<year>2009</year>) <volume>46</volume>:<fpage>553</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1136/jmg.2009.067140</pub-id><pub-id pub-id-type="pmid">19465406</pub-id></mixed-citation>
</ref>
<ref id="B132">
<label>132</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasquier</surname><given-names>B</given-names></name><name><surname>Yin</surname><given-names>L</given-names></name><name><surname>Fondaneche</surname><given-names>MC</given-names></name><name><surname>Relouzat</surname><given-names>F</given-names></name><name><surname>Bloch-Queyrat</surname><given-names>C</given-names></name><name><surname>Lambert</surname><given-names>N</given-names></name><etal></etal></person-group>
<article-title>Defective NKT cell development in mice and humans lacking the adapter SAP, the X-linked lymphoproliferative syndrome gene product</article-title>. <source/>J Exp Med (<year>2005</year>) <volume>201</volume>:<fpage>695</fpage>–<lpage>701</lpage>.<pub-id pub-id-type="doi">10.1084/jem.20042432</pub-id><pub-id pub-id-type="pmid">15738056</pub-id></mixed-citation>
</ref>
<ref id="B133">
<label>133</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gadue</surname><given-names>P</given-names></name><name><surname>Stein</surname><given-names>PL</given-names></name></person-group>. <article-title>NK T cell precursors exhibit differential cytokine regulation and require Itk for efficient maturation</article-title>. <source/>J Immunol (<year>2002</year>) <volume>169</volume>:<fpage>2397</fpage>–<lpage>406</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.169.5.2397</pub-id><pub-id pub-id-type="pmid">12193707</pub-id></mixed-citation>
</ref>
<ref id="B134">
<label>134</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Felices</surname><given-names>M</given-names></name><name><surname>Berg</surname><given-names>LJ</given-names></name></person-group>. <article-title>The Tec kinases Itk and Rlk regulate NKT cell maturation, cytokine production, and survival</article-title>. <source/>J Immunol (<year>2008</year>) <volume>180</volume>:<fpage>3007</fpage>–<lpage>18</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.180.5.3007</pub-id><pub-id pub-id-type="pmid">18292523</pub-id></mixed-citation>
</ref>
<ref id="B135">
<label>135</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Gorentla</surname><given-names>BK</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Stone</surname><given-names>JC</given-names></name><name><surname>Zhong</surname><given-names>XP</given-names></name></person-group>. <article-title>Critical roles of RasGRP1 for invariant NKT cell development</article-title>. <source/>J Immunol (<year>2011</year>) <volume>187</volume>:<fpage>4467</fpage>–<lpage>73</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1003798</pub-id><pub-id pub-id-type="pmid">21957144</pub-id></mixed-citation>
</ref>
<ref id="B136">
<label>136</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nichols</surname><given-names>KE</given-names></name><name><surname>Hom</surname><given-names>J</given-names></name><name><surname>Gong</surname><given-names>SY</given-names></name><name><surname>Ganguly</surname><given-names>A</given-names></name><name><surname>Ma</surname><given-names>CS</given-names></name><name><surname>Cannons</surname><given-names>JL</given-names></name><etal></etal></person-group>
<article-title>Regulation of NKT cell development by SAP, the protein defective in XLP</article-title>. <source/>Nat Med (<year>2005</year>) <volume>11</volume>:<fpage>340</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1038/nm1189</pub-id><pub-id pub-id-type="pmid">15711562</pub-id></mixed-citation>
</ref>
<ref id="B137">
<label>137</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>R</given-names></name><name><surname>Bassiri</surname><given-names>H</given-names></name><name><surname>Guan</surname><given-names>P</given-names></name><name><surname>Wiener</surname><given-names>S</given-names></name><name><surname>Banerjee</surname><given-names>PP</given-names></name><name><surname>Zhong</surname><given-names>MC</given-names></name><etal></etal></person-group>
<article-title>The adaptor molecule SAP plays essential roles during invariant NKT cell cytotoxicity and lytic synapse formation</article-title>. <source/>Blood (<year>2013</year>) <volume>121</volume>:<fpage>3386</fpage>–<lpage>95</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2012-11-468868</pub-id><pub-id pub-id-type="pmid">23430111</pub-id></mixed-citation>
</ref>
<ref id="B138">
<label>138</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerart</surname><given-names>S</given-names></name><name><surname>Siberil</surname><given-names>S</given-names></name><name><surname>Martin</surname><given-names>E</given-names></name><name><surname>Lenoir</surname><given-names>C</given-names></name><name><surname>Aguilar</surname><given-names>C</given-names></name><name><surname>Picard</surname><given-names>C</given-names></name><etal></etal></person-group>
<article-title>Human iNKT and MAIT cells exhibit a PLZF-dependent proapoptotic propensity that is counterbalanced by XIAP</article-title>. <source/>Blood (<year>2013</year>) <volume>121</volume>:<fpage>614</fpage>–<lpage>23</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2012-09-456095</pub-id><pub-id pub-id-type="pmid">23223428</pub-id></mixed-citation>
</ref>
<ref id="B139">
<label>139</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>BK</given-names></name><name><surname>Tsai</surname><given-names>K</given-names></name><name><surname>Allan</surname><given-names>LL</given-names></name><name><surname>Zheng</surname><given-names>DJ</given-names></name><name><surname>Nie</surname><given-names>JC</given-names></name><name><surname>Biggs</surname><given-names>CM</given-names></name><etal></etal></person-group>
<article-title>Innate immune control of EBV-infected B cells by invariant natural killer T cells</article-title>. <source/>Blood (<year>2013</year>) <volume>122</volume>:<fpage>2600</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2013-01-480665</pub-id><pub-id pub-id-type="pmid">23974196</pub-id></mixed-citation>
</ref>
<ref id="B140">
<label>140</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuling</surname><given-names>H</given-names></name><name><surname>Ruijing</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Xiang</surname><given-names>J</given-names></name><name><surname>Rui</surname><given-names>Z</given-names></name><name><surname>Yujuan</surname><given-names>W</given-names></name><etal></etal></person-group>
<article-title>EBV-induced human CD8+ NKT cells suppress tumorigenesis by EBV-associated malignancies</article-title>. <source/>Cancer Res (<year>2009</year>) <volume>69</volume>:<fpage>7935</fpage>–<lpage>44</lpage>.<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-0828</pub-id><pub-id pub-id-type="pmid">19808969</pub-id></mixed-citation>
</ref>
<ref id="B141">
<label>141</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>R</given-names></name><name><surname>Xiao</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Ji</surname><given-names>X</given-names></name><etal></etal></person-group>
<article-title>EBV-induced human CD8(+) NKT cells synergise CD4(+) NKT cells suppressing EBV-associated tumours upon induction of Th1-bias</article-title>. <source/>Cell Mol Immunol (<year>2009</year>) <volume>6</volume>:<fpage>367</fpage>–<lpage>79</lpage>.<pub-id pub-id-type="doi">10.1038/cmi.2009.48</pub-id><pub-id pub-id-type="pmid">19887050</pub-id></mixed-citation>
</ref>
<ref id="B142">
<label>142</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okada</surname><given-names>S</given-names></name><name><surname>Markle</surname><given-names>JG</given-names></name><name><surname>Deenick</surname><given-names>EK</given-names></name><name><surname>Mele</surname><given-names>F</given-names></name><name><surname>Averbuch</surname><given-names>D</given-names></name><name><surname>Lagos</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>IMMUNODEFICIENCIES. Impairment of immunity to <italic>Candida</italic> and <italic>Mycobacterium</italic> in humans with bi-allelic RORC mutations</article-title>. <source/>Science (<year>2015</year>) <volume>349</volume>:<fpage>606</fpage>–<lpage>13</lpage>.<pub-id pub-id-type="doi">10.1126/science.aaa4282</pub-id><pub-id pub-id-type="pmid">26160376</pub-id></mixed-citation>
</ref>
<ref id="B143">
<label>143</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azzi</surname><given-names>T</given-names></name><name><surname>Lunemann</surname><given-names>A</given-names></name><name><surname>Murer</surname><given-names>A</given-names></name><name><surname>Ueda</surname><given-names>S</given-names></name><name><surname>Beziat</surname><given-names>V</given-names></name><name><surname>Malmberg</surname><given-names>KJ</given-names></name><etal></etal></person-group>
<article-title>Role for early-differentiated natural killer cells in infectious mononucleosis</article-title>. <source/>Blood (<year>2014</year>) <volume>124</volume>:<fpage>2533</fpage>–<lpage>43</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2014-01-553024</pub-id><pub-id pub-id-type="pmid">25205117</pub-id></mixed-citation>
</ref>
<ref id="B144">
<label>144</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vely</surname><given-names>F</given-names></name><name><surname>Barlogis</surname><given-names>V</given-names></name><name><surname>Vallentin</surname><given-names>B</given-names></name><name><surname>Neven</surname><given-names>B</given-names></name><name><surname>Piperoglou</surname><given-names>C</given-names></name><name><surname>Ebbo</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Evidence of innate lymphoid cell redundancy in humans</article-title>. <source/>Nat Immunol (<year>2016</year>) <volume>17</volume>:<fpage>1291</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1038/ni.3553</pub-id><pub-id pub-id-type="pmid">27618553</pub-id></mixed-citation>
</ref>
<ref id="B145">
<label>145</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>GB</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name><name><surname>Lee</surname><given-names>HK</given-names></name><name><surname>Song</surname><given-names>H</given-names></name><name><surname>Cho</surname><given-names>DH</given-names></name><name><surname>Lee</surname><given-names>WJ</given-names></name><etal></etal></person-group>
<article-title>Endoplasmic reticulum stress-mediated apoptosis of EBV-transformed B cells by cross-linking of CD70 is dependent upon generation of reactive oxygen species and activation of p38 MAPK and JNK pathway</article-title>. <source/>J Immunol (<year>2010</year>) <volume>185</volume>:<fpage>7274</fpage>–<lpage>84</lpage>.<pub-id pub-id-type="doi">10.4049/jimmunol.1001547</pub-id><pub-id pub-id-type="pmid">21078900</pub-id></mixed-citation>
</ref>
<ref id="B146">
<label>146</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sepulveda</surname><given-names>FE</given-names></name><name><surname>de Saint Basile</surname><given-names>G</given-names></name></person-group>. <article-title>Hemophagocytic syndrome: primary forms and predisposing conditions</article-title>. <source/>Curr Opin Immunol (<year>2017</year>) <volume>49</volume>:<fpage>20</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1016/j.coi.2017.08.004</pub-id><pub-id pub-id-type="pmid">28866302</pub-id></mixed-citation>
</ref>
<ref id="B147">
<label>147</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boztug</surname><given-names>H</given-names></name><name><surname>Hirschmugl</surname><given-names>T</given-names></name><name><surname>Holter</surname><given-names>W</given-names></name><name><surname>Lakatos</surname><given-names>K</given-names></name><name><surname>Kager</surname><given-names>L</given-names></name><name><surname>Trapin</surname><given-names>D</given-names></name><etal></etal></person-group>
<article-title>NF-kappaB1 haploinsufficiency causing Immunodeficiency and EBV-driven lymphoproliferation</article-title>. <source/>J Clin Immunol (<year>2016</year>) <volume>36</volume>:<fpage>533</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="doi">10.1007/s10875-016-0306-1</pub-id><pub-id pub-id-type="pmid">27338827</pub-id></mixed-citation>
</ref>
<ref id="B148">
<label>148</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nehme</surname><given-names>NT</given-names></name><name><surname>Schmid</surname><given-names>JP</given-names></name><name><surname>Debeurme</surname><given-names>F</given-names></name><name><surname>Andre-Schmutz</surname><given-names>I</given-names></name><name><surname>Lim</surname><given-names>A</given-names></name><name><surname>Nitschke</surname><given-names>P</given-names></name><etal></etal></person-group>
<article-title>MST1 mutations in autosomal recessive primary immunodeficiency characterized by defective naive T-cell survival</article-title>. <source/>Blood (<year>2012</year>) <volume>119</volume>:<fpage>3458</fpage>–<lpage>68</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2011-09-378364</pub-id><pub-id pub-id-type="pmid">22174160</pub-id></mixed-citation>
</ref>
<ref id="B149">
<label>149</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdollahpour</surname><given-names>H</given-names></name><name><surname>Appaswamy</surname><given-names>G</given-names></name><name><surname>Kotlarz</surname><given-names>D</given-names></name><name><surname>Diestelhorst</surname><given-names>J</given-names></name><name><surname>Beier</surname><given-names>R</given-names></name><name><surname>Schaffer</surname><given-names>AA</given-names></name><etal></etal></person-group>
<article-title>The phenotype of human STK4 deficiency</article-title>. <source/>Blood (<year>2012</year>) <volume>119</volume>:<fpage>3450</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2011-09-378158</pub-id><pub-id pub-id-type="pmid">22294732</pub-id></mixed-citation>
</ref>
<ref id="B150">
<label>150</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>S</given-names></name><name><surname>Scuderi</surname><given-names>R</given-names></name><name><surname>Malicki</surname><given-names>DM</given-names></name><name><surname>Willert</surname><given-names>J</given-names></name><name><surname>Bastian</surname><given-names>J</given-names></name><name><surname>Weidner</surname><given-names>N</given-names></name></person-group>. <article-title>Hodgkin’s and non-Hodgkin’s lymphomas occurring in two brothers with Wiskott-Aldrich syndrome and review of the literature</article-title>. <source/>Pediatr Dev Pathol (<year>2011</year>) <volume>14</volume>:<fpage>64</fpage>–<lpage>70</lpage>.<pub-id pub-id-type="doi">10.2350/10-01-0787-CR.1</pub-id><pub-id pub-id-type="pmid">20429642</pub-id></mixed-citation>
</ref>
<ref id="B151">
<label>151</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aydin</surname><given-names>SE</given-names></name><name><surname>Kilic</surname><given-names>SS</given-names></name><name><surname>Aytekin</surname><given-names>C</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Porras</surname><given-names>O</given-names></name><name><surname>Kainulainen</surname><given-names>L</given-names></name><etal></etal></person-group>
<article-title>DOCK8 deficiency: clinical and immunological phenotype and treatment options – a review of 136 patients</article-title>. <source/>J Clin Immunol (<year>2015</year>) <volume>35</volume>:<fpage>189</fpage>–<lpage>98</lpage>.<pub-id pub-id-type="doi">10.1007/s10875-014-0126-0</pub-id><pub-id pub-id-type="pmid">25627830</pub-id></mixed-citation>
</ref>
<ref id="B152">
<label>152</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>JI</given-names></name></person-group>. <article-title>GATA2 deficiency and Epstein-Barr virus disease</article-title>. <source/>Front Immunol (<year>2017</year>) <volume>8</volume>:<fpage>1869</fpage>.<pub-id pub-id-type="doi">10.3389/fimmu.2017.01869</pub-id><pub-id pub-id-type="pmid">29375553</pub-id></mixed-citation>
</ref>
<ref id="B153">
<label>153</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coulter</surname><given-names>TI</given-names></name><name><surname>Chandra</surname><given-names>A</given-names></name><name><surname>Bacon</surname><given-names>CM</given-names></name><name><surname>Babar</surname><given-names>J</given-names></name><name><surname>Curtis</surname><given-names>J</given-names></name><name><surname>Screaton</surname><given-names>N</given-names></name><etal></etal></person-group>
<article-title>Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: a large patient cohort study</article-title>. <source/>J Allergy Clin Immunol (<year>2016</year>) <volume>139</volume>(<issue>2</issue>):<fpage>597</fpage>–<lpage>606.e4</lpage>.<pub-id pub-id-type="doi">10.1016/j.jaci.2016.06.021</pub-id><pub-id pub-id-type="pmid">27555459</pub-id></mixed-citation>
</ref>
<ref id="B154">
<label>154</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newell</surname><given-names>A</given-names></name><name><surname>Dadi</surname><given-names>H</given-names></name><name><surname>Goldberg</surname><given-names>R</given-names></name><name><surname>Ngan</surname><given-names>BY</given-names></name><name><surname>Grunebaum</surname><given-names>E</given-names></name><name><surname>Roifman</surname><given-names>CM</given-names></name></person-group>
<article-title>Diffuse large B-cell lymphoma as presenting feature of Zap-70 deficiency</article-title>. <source/>J Allergy Clin Immunol (<year>2011</year>) <volume>127</volume>:<fpage>517</fpage>–<lpage>20</lpage>.<pub-id pub-id-type="doi">10.1016/j.jaci.2010.09.016</pub-id><pub-id pub-id-type="pmid">21094993</pub-id></mixed-citation>
</ref>
<ref id="B155">
<label>155</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuetz</surname><given-names>C</given-names></name><name><surname>Huck</surname><given-names>K</given-names></name><name><surname>Gudowius</surname><given-names>S</given-names></name><name><surname>Megahed</surname><given-names>M</given-names></name><name><surname>Feyen</surname><given-names>O</given-names></name><name><surname>Hubner</surname><given-names>B</given-names></name><etal></etal></person-group>
<article-title>An immunodeficiency disease with RAG mutations and granulomas</article-title>. <source/>N Engl J Med (<year>2008</year>) <volume>358</volume>:<fpage>2030</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1056/NEJMoa073966</pub-id><pub-id pub-id-type="pmid">18463379</pub-id></mixed-citation>
</ref>
<ref id="B156">
<label>156</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Felgentreff</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>YN</given-names></name><name><surname>Frugoni</surname><given-names>F</given-names></name><name><surname>Du</surname><given-names>L</given-names></name><name><surname>van der Burg</surname><given-names>M</given-names></name><name><surname>Giliani</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Functional analysis of naturally occurring DCLRE1C mutations and correlation with the clinical phenotype of ARTEMIS deficiency</article-title>. <source/>J Allergy Clin Immunol (<year>2015</year>) <volume>136</volume>:<fpage>140</fpage>–<lpage>150.e7</lpage>.<pub-id pub-id-type="doi">10.1016/j.jaci.2015.03.005</pub-id><pub-id pub-id-type="pmid">25917813</pub-id></mixed-citation>
</ref>
<ref id="B157">
<label>157</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marsh</surname><given-names>RA</given-names></name><name><surname>Rao</surname><given-names>K</given-names></name><name><surname>Satwani</surname><given-names>P</given-names></name><name><surname>Lehmberg</surname><given-names>K</given-names></name><name><surname>Muller</surname><given-names>I</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><etal></etal></person-group>
<article-title>Allogeneic hematopoietic cell transplantation for XIAP deficiency: an international survey reveals poor outcomes</article-title>. <source/>Blood (<year>2013</year>) <volume>121</volume>:<fpage>877</fpage>–<lpage>83</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2012-06-432500</pub-id><pub-id pub-id-type="pmid">23131490</pub-id></mixed-citation>
</ref>
<ref id="B158">
<label>158</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Worth</surname><given-names>AJ</given-names></name><name><surname>Nikolajeva</surname><given-names>O</given-names></name><name><surname>Chiesa</surname><given-names>R</given-names></name><name><surname>Rao</surname><given-names>K</given-names></name><name><surname>Veys</surname><given-names>P</given-names></name><name><surname>Amrolia</surname><given-names>PJ</given-names></name></person-group>
<article-title>Successful stem cell transplant with antibody-based conditioning for XIAP deficiency with refractory hemophagocytic lymphohistiocytosis</article-title>. <source/>Blood (<year>2013</year>) <volume>121</volume>:<fpage>4966</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1182/blood-2013-01-478735</pub-id><pub-id pub-id-type="pmid">23766462</pub-id></mixed-citation>
</ref>
<ref id="B159">
<label>159</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ono</surname><given-names>S</given-names></name><name><surname>Okano</surname><given-names>T</given-names></name><name><surname>Hoshino</surname><given-names>A</given-names></name><name><surname>Yanagimachi</surname><given-names>M</given-names></name><name><surname>Hamamoto</surname><given-names>K</given-names></name><name><surname>Nakazawa</surname><given-names>Y</given-names></name><etal></etal></person-group>
<article-title>Hematopoietic stem cell transplantation for XIAP deficiency in Japan</article-title>. <source/>J Clin Immunol (<year>2017</year>) <volume>37</volume>:<fpage>85</fpage>–<lpage>91</lpage>.<pub-id pub-id-type="doi">10.1007/s10875-016-0348-4</pub-id><pub-id pub-id-type="pmid">27815752</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>